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Abstract
Interactions between Stem Cell Factor (SCF) and c-Kit are critical in maintaining β-cell
survival and function. VEGF-A, essential in facilitating islet vasculature formation, is
secreted by β-cells. This work investigates the mechanisms by which c-Kit regulates VEGFA production in β-cells, using a rat insulinoma (INS-1) cell line as an in vitro model. Cells
were treated with recombinant hSCF or cultured with c-Kit (r) siRNA for 72 h. VEGF-A
accumulation in the culture medium was measured by ELISA, while qRT-PCR, western blot,
and immunofluorescence analyses were also performed. SCF augmented VEGF-A
production in a time-dependent (p < 0.05 vs. control at 6 h and 24 h), and dose-dependent
manner (p < 0.01 vs. control at 30-100 ng/mL). SCF stimulation increased phosphorylation
of proteins along the PI3K/Akt/mTOR pathway (p < 0.05 vs. control groups), and decreased
phosphorylation following siRNA treatment. Our results indicate that c-Kit exerts a
regulatory effect on VEGF-A production in β-cells.
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Chapter 1

1

Introduction

1.1 Significance of the Study
Diabetes mellitus (DM) is a chronic condition characterized by loss of glucose
homeostasis that results most commonly from autoimmune attack on β-cells in type 1
DM (~10% of DM cases), peripheral tissue insulin resistance in type 2 DM (~90% of DM
cases), or insulin receptor dysfunction during pregnancy in gestational DM. Patients
suffering from type 1 or 2 DM commonly develop co-morbidities including
cardiovascular disease, peripheral neuropathy, and nephropathy. Current treatment of
diabetes includes an array of medications that increase insulin secretion and sensitivity as
well as injecting exogenous insulin. These methods of treatment, however, are limited in
their capacity to properly manage glucose homeostasis when faced with the progression
of insulin resistance characteristic of DM pathology. Advancements in medical science
have led to a focus on islet transplantation as a promising approach in curing diabetics.
Yet, this procedure is still riddled with issues, with a reported 10% of total patients
remaining free of daily insulin supplementation after a period of five years (Ryan et al.,
2005). One of the main obstacles surrounding islet transplantation is not only the limited
supply of donor islets, but also the maintenance of islet health, including islet vasculature.
Previous studies performed on cell types derived from a variety of tissue, including
keloid fibroblasts, human mast cells, melanocytes, and small cell lung cancer cells,
suggest that c-Kit receptor activation may be linked to regulation of hypoxia inducible
factor-1α (HIF-1α), a transcription factor that is instrumental in the production of
vascular endothelial growth factor-A (VEGF-A). VEGF-A is widely recognized as one of
the most important proangiogenic factors in various murine models (Litz et al., 2006;
Zhang et al., 2006; Monsel et al., 2010).
This work seeks to provide evidence supporting that activation of c-Kit by its ligand,
stem cell factor (SCF), in vitro, stimulates HIF-1α-mediated production of VEGF-A via
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the PI3K/Akt/mTOR pathway, previously identified to be activated both in vitro and in
vivo by c-Kit ligand-binding (Li et al., 2006; Li et al., 2007; Feng et al., 2012b). This
study aims to further explore a basis for c-Kit as a potential cell-based therapeutic target,
particularly for pro-angiogenic signaling-aided reconstruction of a dense, fenestrated
capillary network that islets require in maintaining function and survival. Previous studies
in our laboratory have shown that SCF immunoreactivity in the developing human
pancreas was found in the duct regions and scattered throughout the fetal pancreas,
including endocrine cells (Li et al., 2006), and SCF mRNA and protein levels was
detected in the isolated mouse islets (Feng et al., 2012).

1.2 The Pancreas
The pancreas is a “dual organ” consisting of two major compartments: exocrine and
endocrine, composed primarily of exocrine acinar cells, endocrine cells, and ductal cells,
as well as a high degree of vascularisation in the endocrine compartment (Moore and
Dalley, 1999). Most studies on normal insulin secretion and pancreatic development have
utilized rodent islets or clonal cell lines, which have been proven to develop and respond
to insulin secretagogues similarly to human islets, thus providing an apt model for studies
on endocrine cell function and structure (MacDonald et al., 2011). Conversely, clonal cell
lines have their limitations, as they are succeptible to transformation and alteration of
genotype over time of the culture and must be periodically assessed for function in order
to rule out allelic imbalances and normal-cell contamination. In this case, recent studies
in our laboratory have tested the INS-1 cells used for proper glucose-response (Riopel et
al., 2013).

1.2.1

The Exocrine and Endocrine Pancreas

The exocrine components of the pancreas comprise most of the organ’s mass and work to
produce and secrete a multitude of enzymes into the intestine, including proteases such as
trypsin and chymotrypsin, pancreatic lipase, and amylase. This amalgamation of enzymes
collectively works to aid in the digestion of macromolecules into more readily absorbable
forms (Slack, 1995; Moore and Dalley, 1999). The endocrine component, constituting
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only ~2% of pancreatic mass, but ~10% of pancreatic blood flow, is made up of
functional units called the Islets of Langerhans (Jansson, 1994; Brunicardi et al., 1996).
Islets are composed of five different cell types. This includes insulin-secreting β-cells,
responsible for glucose uptake in body tissues, and glucagon-secreting α-cells that
stimulate glycogen breakdown to provide peripheral tissue with energy (Slack, 1995;
Moore and Dalley, 1999). Somatostatin-secreting δ-cells, pancreatic polypeptidesecreting PP cells, and ghrelin-secreting ε-cells are present in considerably fewer
numbers (Andralojc et al., 2009). β-cells are of particular importance in current research
due to their regulatory role with respect to carbohydrate metabolism, specifically in
diabetes, a disease that affects multiple organ systems and stems from impairments of
insulin secretion and defects in insulin action.

1.2.2

Pancreatic β-Cells

The most numerous islet cells, comprising 60-80% of the endocrine pancreas, are β-cells,
responsible for secreting the hormone insulin, to reduce blood glucose levels upon
elevated blood glucose concentration, measured by the passage of glucose through
GLUT2 receptors (McCulloch et al., 2011). Once elevated blood glucose levels are
detected by β-cells, insulin secretory response occurs as a biphasic process (Rorsman et
al., 2000; Straub and Sharp, 2002). Transient stimulation of insulin secretion from
granules in the readily releasable pool (<5% of total granule number), induced by
elevation of blood glucose concentration, is followed by gradually developed secondary
stimulation, thought to be an energy-dependent, active process requiring physically
translocating or chemically modifying secretory granules (Rorsman et al., 2000). Insulin
is then able to stimulate anabolic processes, such as glucose uptake by cells of the body
and conversion of glucose to glycogen in the liver (Moore and Dalley, 1999). This effect
is counterbalanced by α-cell-mediated glucagon release, stimulating glycogenolysis and
gluconeogenesis.
β-cells produce a variety of other hormones and exert effects on the pancreatic
microenvironment besides insulin detection and secretion. Under high concentrations of
glucose or other environmental stressors, it has been found that β-cells begin to produce
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proinflammatory cytokines, caused by accumulation of molecules such as tumor necrosis
factor (TNF) and lymphotoxin α, which are important contributing factors to suppression
of β-cell function and subsequent apoptosis in type 1 diabetics (Kagi et al., 1999; Eizirik
et al., 2009). Besides cytokine-mediated pancreatic dysfunction, it is widely reported that
β-cells, due to their dependency on islet vasculature, are influenced by a variety of
proangiogenic factors, such as angiopoietin-2, and antiangiogenic factors, such as
thrombospondin-1. These molecules are found in the microenvironment, and are able to
provide positive and negative control for islet vasculature development, maintenance, and
reconstruction. VEGF-A is secreted by β-cells, and is found to play a critical, nonredundant role in angiogenic switching, a process that is characterized by a change in the
balance of proangiogenic and antiangiogenic factors that allows tumors to develop in size
and metastatic poetential, and pancreatic β-cell carcinogenesis (Folkman, 2002; Inoue et
al., 2002). By modulation of these signaling molecules, mature β-cells are able to interact
with intra-islet endothelial cells that create a supportive environment that is conducive to
their survival and function. For example, recruited endothelial cells are able to synthesize
the basement membrane laminin chains α4 and α5 to upregulate insulin gene expression
and β-cell proliferation by interacting with laminin receptors containing β1-integrin
(Nikolova et al., 2006). Additionally, β-cell-secreted angiogenic factors are required to
maintain endothelial cell morphology which, in turn, allows for maintenance of their own
structure and morphology (Figure 1.1) (Lammert et al., 2003).

1.3 The INS-1 Cell Line
Insulin-secreting cell lines (INS-1 and INS-2) were established using cells isolated from
an x-ray-induced rat transplantable insulinoma. This cell line is unique, compared to
those previously used, in that it retains features characteristic of physiological β-cells
including morphology, insulin biosynthesis, and secretion. Unfortunately, similar to the
phenotype observed in the parent tumor in vivo, these cells have a limited capacity for
glucose-stimulated insulin secretion and are unable to synthesize and store normal levels
of insulin. Compared to hamster beta cell lines, derived from hamster islet cells by SV40,
and β-TC lines, derived from transgenic mice, INS-1 cells are able to retain glucose
responsiveness and insulin content with increasing passage numbers (Asfari et al., 1992).
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Figure 1.1 Schematic of inter-islet relationship between endothelial cell and βcell.
Endothelial cells promote β-cell proliferation, survival and function by secreting
hepatocyte growth factors (HGF), thrombospondin-1 (TSP-1), laminins, collagens.
β-cells promote endothelial cell proliferation, vessel sprouting and angiogenic
processes by secreting insulin, vascular endothelial growth factor-A (VEGF-A),
and angiopoietin-1 (Ang-1) (Cao and Wang, 2014).
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Several daughter cell lines were derived from the INS-1 and INS-2 cell lines, including
INS-1 832, INS-1 832/2, and INS-1 832/13. The INS-1 832 and INS-1 832/2 cell lines
exhibit higher insulin content than their parental cell lines. Due to low levels or
insensitivity to cAMP, a molecule required in maintaining primary β-cells in a glucose
competent state, these cell lines demonstrate relatively poor or unresponsive glucosestimulated insulin secretion (Yang et al., 2004). INS-1 832/13 cells, used in this study,
were found to be very sensitive to cAMP, as evidenced by a relatively enhanced level of
insulin

secretion

compared

to

INS-1

832/2

cells

following

forskolin

or

isobutylmethylxanthine stimulation or decreased insulin secretion when treated with a
protein kinase A (PKA) inhibitor (Yang et al., 2004). Furthermore, when the regulatory
subunit of PKA was overexpressed in the 832/13 cells, insulin secretion and PKA activity
were severely inhibited (Yang et al., 2004). The glucose effect on this cell line is
potentiated by insulin secretory agents such as IBMX, GLP-1, free fatty acids and
sulfonylurea tolbutamide, and inhibited by potassium channel openers, with responses
similar to adult rodent β-cells (Hohmeier et al., 2000). Importantly, INS-1 832/13 cells
express Glut2 receptors and uses glucokinase, as opposed to hexokinase, to
phosphorylate intracellular glucose (Skelin et al., 2010). Finally, the INS-1 832/13 cell
line is derived from an insulinoma, it has endogenous proangiogenic factor production to
support tumor growth, though it lacks a microenvironment that would normally create a
balance between positive and negative angiogenic signal regulation. For these reasons,
despite some limitations, the following study made use of the INS-1 832/13 cell line, due
to their physiological resemblance to normal adult β-cells, compared to other available
cell lines. Thus, manipulation of this cell line allows for insight into the mechanism
behind disease state resulting from impairment of β-cells.

1.4 Diabetes Mellitus (DM)
Diabetes mellitus, screened and diagnosed by standards based on the World Health
Organization (WHO) and Canadian Diabetes Association (CDA) criteria, is defined as an
illness of the endocrine pancreas characterized by hyperglycemia, insulin resistance, and
relative insulin deficiency (CDA, 2008). It is estimated that in 2011, 347 million people
around the world were diabetic and diabetes is on track to become the 7th leading cause of

8

death worldwide by 2030 (WHO, 2009; Danaei et al., 2011). In 2009, it was estimated by
the CDA that over 2.3 million Canadians were living with diabetes, with 6 million others
at elevated risk. It has been reported that, in 2009, the strain of diabetes on the Canadian
healthcare system was $12.2 billion annually, projected to rise to $16.9 billion by 2020
(CDA, 2008; Gougeon et al., 2014).
Diabetes mellitus can be broken down into three subtypes: type 1 diabetes (insulindependent), type 2 diabetes (non-insulin dependent), and gestational diabetes (GDM)
(WHO, 2009). In type 1 diabetes, which comprises ~10% of the total diabetic population,
pancreatic β-cells are destroyed by an autoimmune attack, resulting in the inability to
produce and secrete insulin. Onset of type 1 diabetes typically occurs in children and
young adults and is treated by insulin injections to normalize blood glucose (American
Diabetes Association, 2010; Florez, 2014). Type 2 diabetes, comprising ~90% of all
diabetes, is believed to be caused by a combination of genetic factors, such as carrying
TCF7L2 allele, and lifestyle factors, such as poor diet, lack of exercise, and obesity. Type
2 diabetes’ onset generally occurs toward middle age and can be characterized by insulin
resistance in body tissues (primarily muscle, adipose, and liver) and often deficiency in
insulin production and secretion, due to decreased β-cell mass (American Diabetes
Association, 2010; Florez, 2014). Type 2 diabetes is a multifactorial illness, contributed
to by the accumulation of many genetic and physiological factors exacerbated by
oxidative stress caused by elevated glucose. This can result in an increase of
mitochondrial reactive oxygen species (ROS) production, nonenzymatic glycation of
proteins, and glucose autoxidation. Additionally, a variety of transcription factors and
signaling pathways have been known to be activated by hyperglycemia, including NfκB,
p38 MAPK and JNK/SAPK activation, all known to be activated by hyperglycemia,
ROS, and accumulation of inflammatory cytokines (Evans et al., 2002). The
simultaneous and additive exacerbation of these pathways is thought to play a part in the
development of type 2 diabetes. GDM occurs during pregnancy, diagnosed in women that
had not previously exhibited elevated blood glucose levels, and often resolves following
delivery. Women are normally screened for high levels of glucose in order to provide
treatment and management of GDM, typically with dietary adjustment, exogenous fastacting insulin injection, or medications such as metformin and glyburide (McIntyre et al.,
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2014). Complications associated with diabetes include significantly increased risk of
cardiovascular disease, diabetic retinopathy, diabetic neuropathy, and a slew of other
comorbidities that result in a shortened lifespan with a lower quality of life (American
Diabetes Association, 2010; Florez, 2014).
Currently, administration of exogenous insulin is the primary treatment for type 1
diabetes, and advanced cases of type 2 diabetes, but only mitigates the negative effects
and, as such, is not considered a cure for the illness. Type 2 diabetics are typically
managed with a variety of lifestyle and dietary changes, and pharmacological treatments
including increasing insulin secretion and sensitivity, β-cell replication and survival
(Turner et al., 1998; Knowler et al., 2002; Jos et al., 2005). An alternative to exogenous
insulin has emerged recently, in the form of islet transplantation. The Edmonton protocol
is a popular islet transplantation procedure that has allowed patients to remain insulinindependent after approximately a year. It involves isolation of islets from several
cadaveric donor pancreata, and infusion into a patient’s hepatic portal vein, supplemented
by a regimen of immunosuppressants in order to avoid autoimmune-mediated rejection
(Shapiro et al., 2000). Unfortunately, a variety of issues exist with this procedure, since it
moves islets into the hypoxic environment of the hepatic portal vein and there is a
scarcity of donor tissue (Ryan et al., 2002).
As previously mentioned, pancreatic islets exhibit a high degree of vascularisation, which
is important for their ability to quickly secrete insulin in response to changes in blood
glucose and to effectively deliver insulin to peripheral tissues. It is known that the
procedure of pancreatic islet isolation severs the connections between islet vasculature
and systemic circulation. This renders transplanted islets avascular for several days
following the procedure, with overall less islet vascularisation and lower oxygen tension,
compared to native pancreatic islets, even once vascularization has completed (Brissova
et al., 2014; Irving-Rodgers et al., 2014). This work examines the possibility of a cellbased therapeutic approach to combat significant islet cell death due to ischemia and
compensate for impaired vasculogenesis following transplantation by targeting the
receptor tyrosine kinase (RTK), c-Kit, which has already been shown to play an
important role in β-cell survival, migration, and function in vivo. c-Kit signaling as a cell-
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based therapy for enhancement of β-cell function has been previously demonstrated by
transplantation of bone marrow-derived c-Kit-expressing cells that resulted in initation of
islet regeneration in streptozotocin-treated non-obese diabetic/severe combined
immunodefficient (NOD/SCID) mice (Hess et al., 2003). Since one of the main issues
with islet transplantation, as opposed to a regiment of exogenous insulin delivery, is the
limitations of islet donors, it is crucial to ensure maximum islet survival and function in
the long term by improving post-transplant vasculogenic function (Brissova, 2008). Thus,
applying similar protocols following islet transplantation in order to aid in β-cell survival
and revascularization is potentially a viable course of treatment.

1.5 c-Kit Receptor Tyrosine Kinase and Stem Cell Factor
1.5.1

c-Kit Receptor Tyrosine Kinase

c-Kit (CD-117), a class III receptor tyrosine kinase (RTK) structurally similar to the
colony stimulating factor-1 receptor (CSF-1R) and the platelet-derived growth factor
receptor (PDGFR), is encoded by the c-Kit proto-oncogene (Yarden et al., 1987). The ckit gene has been mapped to the dominant white spotting (W) locus on mouse
chromosome 5 and human chromosome 4q11-q21 with two or four reported isoforms in
mice and humans, respectively, as a result of alternative splicing. These isoforms are
characterized by the presence or absence the tetrapeptide sequence, Gly-Asn-Asn-Lys
(GNNK), in the extracellular domain and, in humans, the presence or absence of a serine
residue in the interkinase region of the cytoplasmic domain (Geissler et al., 1988). The cKit isoform lacking the tetrapeptide sequence has been shown to induce stronger but
transient signals and have a higher transforming ability, compared to its GNNK-included
counterpart (Caruana et al., 1999; Voytyuk et al., 2003).
c-Kit is a transmembrane protein containing an extracellular domain, a single
transmembrane region, an inhibitory cytoplasmic juxtamembrane domain, and a split
cytoplasmic kinase domain separated by a kinase insert segment (Figure 1.2)
(Lennartsson and Ronnstrand, 2006). The extracellular region is composed of five
immunoglobulin-like domains, the first three of which form a concave surface that serves
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Figure 1.3 Schematic of c-Kit, a transmembrane receptor tyrosine kinase.
The extracellular region is composed of five immunoglobulin-like domains, the first three
of which form a concave surface serving as a ligand-binding site for stem cell factor (SCF).
The fourth and fifth domains play a role in receptor dimerization. The intracellular region is
composed of a juxtamembrane domain with an ATP-binding region and a
phosphotransferase region, containing 9 identified phosphorylation sites, split by a 77
amino acid kinase insert and a COOH tail (Ashman, 1999).
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as a ligand binding site for Stem Cell Factor (SCF). The fourth and fifth domain,
however, are thought to play a role in c-Kit dimerization (Lev et al., 1992; Blechman et
al., 1995). Additionally, the fifth domain is thought to allow the c-Kit receptor to be
cleaved by proteases to allow shedding from the membranes of hematopoietic, mast, and
endothelial cells (Pandiella et al., 1992). The intracellular region of c-Kit is composed of
a juxtamembrane domain with an ATP-binding region and a phosphotransferase region
containing multiple autophosphorylation sites, split by a 77 amino acid kinase insert, and
a COOH tail (Brannan et al., 1992; Linnekin, 1999).

1.5.2

Stem Cell Factor

SCF, c-Kit’s ligand, is a cytokine produced by keratinocytes, fibroblasts and endothelial
cells as well as endocrine cells in either a soluble form or as a transmembrane protein
after alternative splicing and proteolytic cleavage of 8 exons that, upon binding to c-Kit,
is linked to growth and differentiation of melanocytes, hematopoietic, mast, germ, and
pancreatic islet cells (Tajima et al., 1998; Li et al., 2006; Feng et al., 2012). It has been
shown that several cancer cell lines are also able to produce low amounts of soluble SCF
(Beck et al., 1995). SCF has been mapped to the Steel (Sl) locus on mouse chromosome
10 and human chromosome 12q22-24, expressed as four or six isoforms in mice and
humans, respectively, following alternative splicing (Martin et al., 1990; Zsebo et al.,
1990). Of these, two transcripts are mainly expressed, encoding membrane-bound SCF,
that can be cleaved by the metalloproteinase MMP-9, to form a third soluble form, with
an extracellular domain, transmembrane domain, and an intracellular region (Figure 1.3)
(Anderson et al., 1990; Majumdar et al., 1994; Oriss et al., 2014). The first form of SCF
is membrane-bound SCF248, a 45 kD glycoprotein, which can be cleaved by proteases at
the sixth exon to produce soluble SCF165. The second isoform, SCF220, a 32 kD
glycoprotein, lacks a sixth exon and thus remains bound to the membrane, however can
be cleaved at a secondary cleavage site located, in mice, at the seventh exon to create a
soluble form (Majumdar et al., 1994). Both the transmembrane and soluble forms of SCF
have been found to be biologically active, but serve different functions in mediating the
effects of c-Kit. For example, experiments performed with Sl/Sld mouse models that
produce either only soluble SCF or only membrane-bound SCF, show that the
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Figure 1.4 Schematic of the three forms of SCF primarily expressed in rodents.
Two membrane-bound isoforms of SCF include SCF220 and SCF248, while SCF165 is soluble.
SCF 248, a 45 kD glycoprotein can be cleaved at the sixth or seventh exon to form soluble
SCF165. SCF220, a 32 kD glycoprotein, lacks a sixth exon, but can be cleaved at the seventh exon
to create soluble SCF165. All forms of SCF are biologically active, however membrane-bound
SCF is able to readily form dimers, and is responsible for persistent activation and a prolonged
lifespan of c-Kit, whereas soluble SCF induces transient receptor activation and enhances c-Kit
protein degradation (Ashman, 1999).
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membrane-bound form was able to partially recover from anemia, bone marrow
hypocellularity, and runting, while the soluble form restored myeloid progenitor cell
numbers (Kapur et al., 1998). It has been shown that membrane-bound SCF is able to
form dimers, which are more biologically active than monomers (Kurosawa et al., 1996).
Soluble SCF, however, has been shown to exist primarily in monomer form, where it is
less potent in activating c-Kit. Evidence has shown that membrane-bound SCF is
responsible for persistent activation and a prolonged lifespan of c-Kit, whereas soluble
SCF induces transient receptor activation and enhances c-Kit protein degradation (Philo
et al., 1996; Lemmon et al., 1997).

1.5.3

c-Kit Receptor Tyrosine Kinase & Signaling Pathways

c-Kit signaling begins as SCF forms homodimers and binds to the three extracellular
immunoglobulin domains located on the c-Kit receptor. This process is stimulated by
binding of the SCF dimer to two receptor monomers (Lemmon et al., 1997). c-Kit
dimerization results in subsequent autophosphorylation of tyrosine residues, located
primarily outside the kinase domain (Blume-Jensen et al., 1995; Lemmon et al., 1997).
These phosphorylated tyrosine residues are then able to mediate binding and activation of
signaling molecules within the cytoplasm that have Src homology 2 (SH2) or phosphortyrosine binding (PTB) domains. In the c-Kit RTK, a total of nine potential
phosphorylation residues have been identified (in rodents: Tyr566, 568, 701, 719, 728,
745, 821, 898, and 934) (Figure 1.2) that serve as high-affinity binding sites for signal
transduction molecules (Ronnstrand, 2004). Phosphorylation of these sites can yield
activation of several major intracellular signaling pathways. Phosphorylation at Y719
results in activation of the phosphatidyl-inositol-3 kinase (PI3K) pathway, which
promotes cell survival, migration and proliferation (Young et al., 2006). Phosphorylation
at Y701 and Y934 causes an association with the adapter protein Grb2, which links to the
Ras/Erk pathway through association with SHP-2. This complex is then able to begin a
signaling cascade, which results in the activation of mitogen-activated protein kinase
(MAPK), a signaling molecule that can act on transcription factors to modulate gene
expression, and is essential for cell survival and proliferation (Ronnstrand, 2004; Sun et
al., 2007).
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Phosphorylation at Y566, 568, and 934 results in activation of the v-src avian sarcoma
(Src) pathway, which plays a role in adhesion, chemotaxis, survival, proliferation and
protein trafficking (Price et al., 1997; Thommes et al., 1999; Wollberg et al., 2003).
Furthermore, it has been shown that murine myeloid 32D cells and mouse models with
mutated Y566 and Y568 sites resulted in not only inhibition of the Src pathway, but also
reduced activation of the PI3K, Ras/Erk and Janus kinase/Signal Transducers and
Activators of Transcription (JAK/STAT) pathways (Bondzi et al., 2000; Lennartsson et
al., 2005). These effects were reversed following restoration of Y566 and Y568 to these
mutant models, suggesting that Src, in part, converges with them (Hong et al., 2004;
Ronnstrand, 2004). Phosphorylation at Y728 results in the recruitment of phospholipase
C-γ (PLC-γ), which exists as two isoforms: PLC-γ1 and PLC-γ2. The former is
ubiquitously expressed, while the latter is mainly expressed in the hematopoietic system.
This molecule is responsible for controlling calcium release in cells, a process vital to a
variety of cellular functions (Gommerman et al., 2000).
c-Kit activation is negatively regulated by several cellular mechanisms. Protein kinase C
(PKC) are a family of serine/threonine kinases that serve as regulators for c-Kit and other
RTKs, activated by increases in intracellular levels of diacylglycerol (DAG) (BlumeJensen et al., 1994). In this case, DAG is accumulated by c-Kit-mediated PI3K activation.
This, in turn, stimulates PKC to phosphorylate S741 and S746, serine residues located in
the kinase region of c-Kit that serve to attenuate its downstream signaling capabilities
(Blume-Jensen et al., 1995). Additionally, suppressors of cytokine signaling (SOCS) are
another family of proteins that work to suppress RTKs such as c-Kit. SOCS-1 has been
found to be induced by SCF stimulation of mast cells, binding to c-Kit by its SH2 domain
(Sepulveda et al., 1999; Yasukawa et al., 2000). SOCS-1, specifically, has been shown to
suppress c-Kit-stimulated mitogenesis, but not interfere with survival signals by
occupying Grb2 adaptor proteins via their SH3 domains (Sepulveda et al., 1999; Rottapel
et al., 2002).
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1.5.4

Role of SCF/c-Kit in Islet Biology

Research, performed both in our lab and others, has demonstrated the significance of
SCF/c-Kit interactions in the development and function of the islets of Langerhans,
specifically in regard to β-cell proliferation, maturation and survival (Yashpal et al.,
2004; Li et al., 2007; Rachdi et al., 2001; Oberg-Welsh et al., 1994; LeBras et al., 1998;
Oberg-Welsh and Welsh, 1996). c-Kit mRNA is found at detectable levels by embryonic
day 13 in the rat pancreatic epithelial cells (Oberg-Welsh et al., 1994; LeBras et al.,
1998), as well as in fetal and adult rat islets, but not in acinar cells (Rachdi et al., 2001;
Oberg -Welsh et al., 1994; LeBras et al., 1998; Oberg-Welsh and Welsh, 1996). Previous
studies performed in our lab have demonstrated that c-Kit-expressing human and rat fetal
pancreatic ductal epithelial cells exhibit high proliferation and SCF expression (Yashpal
et al., 2004; Li et al., 2006; Li et al., 2007). Additionally, it was found that ductal cells of
the ligated rat pancreas and islets of streptozotocin-induced diabetic rats had c-Kit
expression, suggesting that c-Kit may play a role in β-cell regeneration (Peters et al.,
2005; Tiemann et al., 2007). In vitro experiments with cultured fetal rat islets treated with
SCF showed a significant increase in insulin and DNA content (Oberg-Welsh and Welsh,
1996). INS-1 cells treated with SCF were found to have an increased proliferative
capacity (Rachdi et al., 2001). In contrast, siRNA-mediated c-Kit knockdown resulted in
reduced islet cell differentiation, associated with a decrease in PDX-1 and insulin mRNA
and protein levels, decreased cell proliferation, and increased cell death (Li et al., 2007).
Taken together, these studies suggest that there is a profound correlation between c-Kit
function and β-cell development and function.
Experiments at the W locus of laboratory mice have demonstrated pleiotropic effects
upon embryonic development and adult hematopoiesis, with most homozygotic mutations
resulting in extensive white-spotting, sterility, and severe anemia resulting in perinatal
mortality (Geissler et al., 1999). To obtain definitive information on c-Kit function in the
β-cell in vivo, our lab used mice with a semi-dominant c-Kit mutation (c-KitWv/+), which
expresses a non-functional c-Kit receptor with a less severe phenotype than c-KitWv/Wv
mice. It has been shown that these mice developed a significant increase in blood glucose
levels by 8 and 16 weeks, lowered insulin levels following glucose stimulation, and islets
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with impaired insulin secretion in response to high glucose. These findings were further
supported by decreases in β-cell mass and insulin content (Krishnamurthy et al., 2007).
These effects were thought to be largely mediated by PI3K and its downstream signaling
molecules, which was confirmed when c-KitWv/+ mice had downregulation of the Fas
pathway by an lpr mutation, or inhibition of Gsk3β by 1-azakenpaullone injection, which
resulted in the reversal of the adverse effects in c-KitWv/+ mice (Feng et al., 2012A; Feng
et al., 2013). Since this is a global mutation affecting every cell in the c-KitWv/+ mice and
does not reveal whether c-Kit has a primary or secondary role in β-cell function, our lab
generated a novel transgenic mouse with β-cell specific c-Kit overexpression (c-KitβTg).
This overexpression not only leads to improved β-cell function, with an increase in Pdx1
and MafA transcription factor expression in normal and high fat diet-induced diabetic
mice, but also prevents the early onset of diabetes observed in c-KitWv/+ mice after crossbreeding (Feng et al., 2012B). Interestingly, we noticed changes in -cell HIF-1 and
VEGF-A expression as well as an alteration of islet capillary mass in c-KitWv/+ mutant
and c-KitTg mice. Taken together, these in vitro and in vivo studies suggest that the
interactions between SCF and c-Kit may play a role in normal vascularization of the islet
through an induction of VEGF-A expression in the -cell.

1.6 Islet Microvasculature and Vascular Endothelial Growth
Factor
1.6.1

Islet Microvasculature

As mentioned previously, the pancreas is a dual organ, consisting of both endocrine and
exocrine tissues. However, there is an asymmetry in the distribution of blood vessels
amongst its two integrated components. While the endocrine tissue comprises ~2% of the
volume of a mature pancreas, the islets of Langerhans scattered throughout the exocrine
pancreas receive ~10% of the organ’s total bloodflow (Jansson and Hellerstrom, 1983).
Blood is supplied to the pancreas by the celiac and superior mesenteric arteries, and
drains into the portal vein (Bonner-Weir and Orci, 1982; Murakami et al., 1992).
Developmental studies based on embryonic growth have determined that there is separate
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vascularisation, ductal drainage, and varied composition of islets. This demonstrates that
the head of the pancreas, composed of pancreatic polypeptide-rich and glucagon-poor
islets, is supplied by the superior mesenteric artery, while the glucagon-rich pancreatic
polypeptide-poor body and tail are supplied by the celiac via the splenic artery (Ohtani,
1983; Ohtani et al., 1986). Interlobular arteries and veins run parallel to major ducts in
the several lobuli that compose the pancreas, and all pancreatic veins empty their
hormone-infused blood into the portal vein (Bockman, 1992). Lymph vessels in the
pancreas are generally not prominent under normal conditions, but a capacity for
drainage of fluids becomes evident during pancreatitis (O’Morchoe, 1997).
Studies in pancreatic vascular flow utilizing ink- or dye-infused whole mounts or
scanning electron microscopy of corrosion casts have determined that islets nest in a
dense glomerular-like capillary network of arterioles such that no endocrine cell is more
than a single cell away from arterial blood supply (Bonner-Weir, 1988). Endocrine
capillaries are highly permeable, comparable to those of the small intestine, due to
possessing relatively high levels of fenestration, reportedly 10 times that of their exocrine
counterparts. Upon morphological analysis, it has been observed that endocrine
capillaries also tend to have a greater diameter than those found in the exocrine pancreas
(Henderson and Moss, 1985; Hart and Pino, 1986). The great density, size, and surface
area of the endocrine capillary network highlights the importance of highly sensitive,
thorough vascularisation that is essential to proper islet function. In the pancreas, it is
thought that vasulature is regulated primarily by vascular endothelial growth factor-A
(VEGF-A) binding to either vascular endothelial growth factor receptors 1 and 2
(VEGFR-1 and VEGFR-2) (Lammert et al., 2003).

1.6.2

VEGF and VEGFR

Vascular endothelial growth factor (VEGF) is a family of signaling proteins that consists
of seven members: VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E, VEGF-F, and
PIGF (Ortega et al., 1999; Carvalho et al., 2007). The monomeric form of these proteins
have a common homology domain composed of a cystine knot motif, with eight cystine
residues involved in inter- and intramolecular disulfide bonds at one end of a four-
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stranded β-sheet, allowing them to dimerize in an antiparallel side-by-side orientation
(Neufeld et al., 1999; Ortega et al., 1999).
VEGF-A, the primary vascular growth factor found in pancreatic β-cells, lung, kidney,
heart, and adrenal gland, has been shown to exist in seven homodimeric isoforms with
monomers consisting of 120, 144, 147, 164, 182, 188, or 205 amino acids in rodents, with
majority appearing in the pancreas as the 120, 164, or 188 amino acid forms (Figure 1.4)
(Qaum et al., 2001; Vasir et al., 2001). There is a single VEGF-A gene coding for eight
exons (Poltorak et al., 1997; Neufeld et al., 1999), with conservation of exons 1 to 5 and
8 in all isoforms, except VEGF-A147, and alternative splicing of heparin-binding domainencoding exons 6 and 7 (Ruhrberg et al., 2002; Hoeben et al., 2004). VEGF-A188, which
contains exon 6, is bound tightly to cell surface heparin-containing proteoglycans in the
extracellular matrix, VEGF-A164 contains exon 7 is moderately diffusible, and VEGFA120, lacking exon 6 or 7, is highly diffusible (Ortega et al., 1999). Upon dimerization,
VEGF proteins are able to bind to three types of RTKs, composed of a 750 amino-acidresidue extracellular domain organized into seven immunoglobulin-like domains, a
transmembrane region, a juxtamembrane domain, a split tyrosine-kinase domain
interrupted by a 70 amino acid kinase insert, and a C-terminal tail, named: the fms-like
tyrosine kinase Flt-1 (VEGFR-1/Flt1), the kinase domain region (VEGFR-2/Flk-1), and
Flt4 (VEGFR-3) (Christinger et al., 2004). In the context of pancreatic islets, VEGFR-1
and VEGFR-2 are expressed almost exclusively on endothelial cells, while functional
endocrine cells, such as β-cells, lack VEGFR expression (Figure 1.4) (Ortega et al.,
1999). VEGFR-2 is the primary receptor responsible for mediating mitosis and migration
of endothelial cells to promote angiogenesis, vasculogenesis, and increased vascular
permeability, by stimulating endothelial production of platelet-activating factor (PAF)
(McMahon, 2000; Hudry-Clergeon et al., 2005). VEGFR-1, containing ligand-binding
site Ig domain-2, exhibits much weaker kinase activity, and is found to have a greater
affinity for VEGF-A, compared to VEGFR-2, containing Ig domain-3 to determine
ligand-binding specificity, suggesting that it is responsible for negatively modulating
pathological vascularisation by competing with VEGFR-2 for substrate (Davis-Smyth et
al., 1996; Shibuya, 2006). However, it has been found that VEGFR-1 may serve a role in
cell migration, chemotaxis, and a minor role in angiogenesis and vasculogenesis (Barleon
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Figure 1.5 Schematic of three isoforms of VEGF-A and two VEGF receptors (VEGFR)
predominantly expressed in rodent pancreas.
The single Vegf-A gene encodes all three isoforms, produced by β-cells, all of which express
exons 1 to 5 and 8. VEGF-A188 contains exon 6 and is bound tightly to cell surface heparincontaining proteoglycans in the extracellular matrix. VEGF-A164 contains exon 7 and is
moderately diffusable. VEGF-A120 lacks exon 6 and 7 and is highly diffusable. VEGF-A can
bind to VEGFR-1 and VEGFR-2 in heterodimeric and homodimeric forms, expressed on
endothelial cells in the pancreas (Hoeben et al., 2004).
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et al., 1996; Tchaikovski et al., 2008). The presence of VEGFR-3 in the body is limited to
lymphatic endothelial cells where activation results in their mitosis, migration,
differentiation, and survival (Achen et al., 1998).

1.6.3

VEGF Signaling

Of the two receptors, VEGFR-1 and VEGFR-2, available in the pancreas for binding by
VEGF-A dimers, VEGFR-2 is responsible for most kinase activity, while VEGFR-1
serves primarily as a negative regulator due to a repressor sequence in the VEGFR-1
juxtamembrane domain. VEGFR-2 activation, however, can lead to autophosphorylation
of a total of six identified tyrosine residues (Y949, Y994, Y1052, Y1057, Y1173, Y1212)
that can recruit an array of important signaling molecules (Olsson et al., 2006).
Phosphorylation of Y1173, a kinase domain residue, creates a binding site for the SH2
domain of PLCγ, which mediates activation of PKC, resulting in generation of
intracellular calcium, and the mitogen-activated protein kinase (MAPK)/extracellular
signal-regulated kinase 1/2 (Erk1/2) pathway, increasing proliferative capacity of
endothelial cells (Ito et al., 1998; Takahashi et al., 2001). Additionally, phosphorylated
Y1173 creates a binding site for the adaptor molecule, Shb, in order to activate the
PI3K/Akt pathway (Sakurai et al., 2005). Active Akt is able to regulate nitric oxide (NO)
production by phosphorylation of endothelial NO synthase (eNOS), allowing for
modulation of vascular permeability (Parenti et al., 1998; Bates and Harper, 2002).
Phosphorylation of Y949 creates a binding site for VEGFR-associated protein (VRAP),
shown to be important in regulating endothelial cell migration (Wu et al., 2000;
Grunewald et al., 2010). Phosphorylation of Y1212 results in activation of the p38MAPK
pathway, resulting in modulation of vascular permeability, and activation of HSP27,
responsible for actin remodeling and cell migration (Holmes et al., 2007). Together, these
effects allow for angiogenesis and vasculogenesis in tissue with increased VEGFR-2
activation.
Several avenues of research have already demonstrated the importance of VEGF
signaling within the context of the pancreas. One study showed that Pdx-1 promoterdependent overexpression of VEGF-A164 led to hypervascularization of the pancreas and
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islet hyperplasia, as well as expression of insulin in cells of the posterior stomach
epithelium (Lammert, 2001). RIP-Cre control of Vegf excision from the genome led to
reduced islet endothelial cells and glucose-stimulated insulin secretion (Watada, 2010).
Another study has linked VEGF-A expression to formation of endothelial cell
fenestrations, an important feature in islet vascular structures (Brissova, 2006).
Developmental studies have shown that mesoderm-derived signals from embryonic blood
vessels are instrumental in supporting pancreas development, preceding the
differentiation of endocrine cells (Lammert, 2001). This observation was further
confirmed in murine homozygous knockouts of VEGFR-2, where expression of Pdx-1 in
the dorsal pancreas remained unchanged, compared to controls, but the bud never
emerged, Pdx-1+ cells were decreased, and Ptf1a expression was lost (Yoshitomi, 2004).
The ventral pancreas in these knockout mice was able to bud normally, but had severe
defects in vasculature, further establishing the essential role that VEGF-A/VEGFR-2
signaling plays in the formation of vascular and pancreatic formation at the embryonic
stage.

1.6.4

Transcription Factor HIF-1α

The primary stimulus for angiogenesis and vasculogenesis is hypoxia (Lin et al., 2004).
The transcription factor monomer, hypoxia-inducible factor 1α (HIF-1α), stable under
hypoxic conditions, is able to bind to the constitutively expressed hypoxia-inducible
factor 1β (HIF-1β) in the cytosol to form an active dimeric form, HIF-1 (Salceda and
Caro, 1997; Richard et al., 1999). VEGF-A expression is closely related to HIF-1
formation and, thus, HIF-1α production, since it has been shown to be induced when cells
are subject to hypoxic or hypoglycemic conditions (Kamiyama et al., 2005; Jeon et al.,
2007). HIF-1 is a heterodimer whose monomeric parts are both basic-helix-loop-helix
per-aryl hydrocarbon receptor nuclear translocator-sim proteins (Forsythe et al., 1996;
Ryan et al., 1998). HIF-1α prolyl hydroxylases (HPH)/prolyl hydroxylase domain
proteins (PHD) 1-3 hydroxylate proline 402 and proline 564, while factor inhibiting HIF1 (FIH-1) is able to hydroxylate asparagine 803 (Semenza, 2001; Semenza, 2007). These
mechanisms are thought to be limited by the cellular presence of O2, allowing for
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regulation of HIF-1 function. Following proline hydroxylation, HIF-1α is able to interact
with von Hippel-Lindau tumor-suppressor protein (VHL), ubiquitinilating it and marking
it for proteosomal degradation. Asparagine hydroxylation prevents HIF-1α interaction
with co-activators CBP and p300, which also serves to inhibit HIF-1α function (Semenza,
2004). The functional HIF-1 imposes its effects on VEGF-A transcript production by
acting in conjuction with coactivator proteins CBP, p300, SRC-1, and TIF-2 to bind to
Hypoxia Regulated/Responsive Element/Enhancer sequences in the 5’ and 3’ regions of
the VEGF-A gene (Ferrara and Davis-Smyth, 1997; Ryan et al., 1998; Dachs and Tozer,
2000; Tsuzuki et al., 2000; Semenza, 2001). In this way, HIF-1 is able to efficiently
modulate vasculogenesis and angiogenesis in mammalian tissue.

1.6.5

Relationship between c-Kit/SCF and VEGF-A

Multiple studies have indicated a possible connection between SCF/c-Kit signaling and
VEGF-A production and secretion in the pancreas. SCF treatment of an H526 small cell
lung cancer cell line showed increased VEGF expression. This effect was shown to be at
least partially dependent on HIF-1 formation and was inhibited by Ly294002 treatment (a
PI3K inhibitor) (Litz and Krystal, 2006). Mammary tumor cell lines transfected with
antisense SCF DNA showed tumors with significantly decreased numbers of mast cells
and decreased microvascular density (Zhang et al., 2000). In adipose tissue-derived stem
cells, VEGFR-2 antagonism and MAPK inhibition resulted in decreased c-Kit expression
(Bai, 2007). Furthermore, c-Kit and VEGF were found to co-localize in human metastatic
melanoma samples (Heissig, 2003). A model of pancreatic islet cancer treated by SU5416
(VEGFR inhibitor) and Gleevec (RTK inhibitor) showed repression of lage-stage tumors
(Bergers, 2003). Gleevec treatment, inhibiting c-Kit and PDGFR, showed significant
reduction of VEGF expression in neuroblastoma cell lines, leading to decreased tumor
volume following injection in SCID mice (Beppu, 2004). Another study found that mast
cell infiltration and activation in tumors was mediated largely by tumor-derived SCF,
indicating that even low concentrations of SCF were able to induce chemotactic
migration of mast cells (Huang et al., 2008). It was reported that in hypoxic MCF-7
breast cancer cells, SCF expression was increased at both the mRNA and protein levels,
and that HIF-1α knockout by RNA interference, SCF expression and c-Kit
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phosphorylation were both significantly reduced (Han et al., 2008). Studies on VEGF-A
have shown a relationship with metalloproteinase MMP-9, a protein that is responsible
for cleavage of membrane-bound SCF as well as neutrophil-mediated activation of
VEGF-A (Christoffersson et al., 2012). Taken together, these studies indicate a definite
link between c-Kit activation and the effects of VEGF-A on mammalian tissues in both in
vitro and in vivo models. However, the role of c-Kit-induced VEGF-A production from
β-cells in islet vascularization and the associated molecular mechanisms are largely
unknown. The purpose of my thesis is to dissect the role of SCF/c-Kit interactions in
regulating β-cell VEGF-A production and associated signaling pathways.

1.7 Objectives, Hypothesis and Specific Questions
1.7.1

Objective

To investigate the functional role of c-Kit in the regulation of β-cell VEGF-A production
and the associated intracellular signaling pathway in an in vitro model.

1.7.2

Hypothesis

An increase in c-Kit activation will stimulate VEGF-A production in β-cells via the
PI3K/Akt/mTOR pathway.

1.7.3

Specific Questions

1. Can VEGF-A production and secretion be stimulated by exogenous activation of
c-Kit in vitro?
2. Will siRNA-mediated knockdown of c-Kit attenuate VEGF-A production and
secretion in vitro?
3. If c-Kit regulates VEGF-A production in β-cells, which intracellular signaling
molecules are involved?
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Chapter 2

2

Research Design and Methods

2.1 Cell Culture and Treatments
INS-1 (832/13) cells (a gift from Dr. Christopher Newgard, Duke University Medical
Center, USA) were thawed in a 37oC waterbath and transferred to a 25 cm2 tissue culture
flask (Corning/VWR; Toronto, ON, Canada) cultured with 3-4 mL of RPMI-1640
medium with L-glutamine and 11.1 mmol/L glucose containing 10% fetal bovine serum
(FBS; Invitrogen; Burlington, ON, Canada), 10 mmol/L HEPES (Sigma; Oakville, ON,
Canada), 1 mmol/L sodium pyruvate (Invitrogen) and 50 μmol/L β-mercaptoethanol
(Sigma) (Jensen et al., 2001; Pederson et al., 2007) . Cells were cultured and expanded at
37oC in an incubator under humidified conditions with 95% air and 5% CO2 to near
(~80%) confluence. Cells were subcultured onto 12-well plates (Corning/VWR) at a
density of 8x104 cells/well and allowed to grow to confluence. Prior to SCF-treatment
and inhibitory experiments, subcultured cells were starved overnight in serum-free 1%
bovine serum albumin (BSA; Sigma) RPMI-1640 medium in order to eliminate the
presence of medium-based growth factors. All experiments are performed at 5-10 passage
of the culture.

2.1.1

Dose and Time of SCF Treatment

After overnight incubation in serum-free RPMI-1640 1% BSA medium, INS-1 cells were
treated with human recombinant SCF (SCF; ID Labs; London, ON, Canada), where the
extracellular domain of human SCF is fused to the N-terminus of the Fc region of a
mutant human IgG1, at dosages of: 10, 20, 30, 50 and 100 ng/mL, or were used as a
control, treated with an SCF vehicle (10 mM acetic acid), for 24 hours. To establish an
optimal treatment time, INS-1 cells were treated with SCF with the optimal dose of SCF
(50 ng/mL) based on the information from the dosage experiments compared to the SCF
vehicle (10 mM acetic acid), and cultured for 1, 6, or 24 hours. At each dose and time-
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point, cell culture medium was collected and stored at -20oC for quantification of VEGFA release using a VEGF-A ELISA.

2.1.2

SCF Treatment of INS-1 Cells

Based on the results from the dose and time study, the dosage of 50 ng/ml and 24 h of
SCF treatment was chosen. Following subculture of INS-1 cells onto 12-well plates,
cells were allowed to grow to ~80% confluence overnight in 10% FBS RPMI-1640
medium. Cell media was then replaced with serum-free 1% BSA RPMI-1640 medium to
starve the cells overnight. Following overnight starving, media was replaced with 600 μL
of fresh 1% BSA RPMI-1640 medium per well, and cells were treated with either SCF at
a concentration of 50 ng/mL or an SCF vehicle (10 mM acetic acid) for 24 hours. At the
end of experiments, INS-1 cells were harvested and washed with phosphate buffered
saline (PBS) and immediately processed for either RNA or protein extraction, or cells
were fixed and embedded in paraffin for immunofluorescence staining analyses. Samples
from at least three to four cell passages per experimental group were collected.

2.1.3

PI3K or mTOR Inhibitory Study in SCF-treated INS-1 Cells

INS-1 cells were prepared and cultured as previously described, and treated with one of
two inhibitors either with or without the presence of SCF. For the PI3K inhibitor study,
INS-1 cells were incubated with Lys294002 (Promega Madison; Madison, WI, USA) at
concentrations of 1, 10, or 100 μmol/L, or untreated with serum-free medium serving as a
control, supplemented with either SCF at a concentration of 50 ng/mL or an SCF vehicle
(10 mM acetic acid), for a period of 24 hours. Lys294002 is able to inhibit PI3K
activation by competing with ATP for the active site of catalytic subunit p110 (Walker et
al., 2000). For the mTOR inhibitor study, INS-1 cells were treated with rapamycin (LC
Laboratories; Woburn, MA, USA) at concentrations of 5, 20, or 100 nmol/L or untreated
with serum-free medium, serving as a control, for 30 minutes prior to the addition of
either SCF at a concentration of 50 ng/mL or an SCF vehicle (10 mM acetic acid) for a
period of 24 hours. Rapamycin is able to impose its effects on mTORC1 formation by
binding to its immunophilin, FK binding protein (FKBP12), which then interacts with
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mTOR to inhibit its function (Dutcher, 2004). In both cases, following the treatment
period, 500 μL of cell media was collected and stored at -20oC for analysis of VEGF
release by ELISA.

2.1.4

Transfection of INS-1 Cells with c-Kit siRNA

INS-1 cells were subcultured onto 12-well plates (Corning/VWR) at a density of 8x104
cells/well and allowed to grow near confluence. Prepared c-Kit (r) siRNA (sc-63363) and
control siRNA (sc-36869, proprietary sequence) (Santa Cruz Biotechnology Inc; Dallas,
TX, USA) transfection mixture per well of 12-well plate: (a) 3.6 μL of siRNA duplex was
added into 60 μL of siRNA Transfection Medium (sc-36868), and (b) 3.6 μL of siRNA
Transfection Reagent (sc-29528) was added into 14.5 μL of siRNA Transfection
Medium. Each mixture was incubated for 5 minutes at room temperature, the siRNA
duplex solution (a) was added directly to the dilute Transfection Reagent (b), mixed
gently, and incubated for 25 minutes at room temperature. As per manufacturer
instructions, 600 μL of fresh 10% FBS DMEM/F12 medium was added to each well
followed by either c-Kit siRNA or control siRNA transfection mixtures. Serum-free
media was not used in accordance to manufacturer instructions, to preserve function and
transfection efficiency that would otherwise be degraded in serum-free media. Cells were
cultured for either 48 or 72 hours at 37oC in a tissue culture incubator. A pool of three
sequences, recommended by the manufacturer to increase the knockdown effect by
targeting three different potential binding sites, for rat c-Kit siRNA (Santa Cruz) were
used: (1) 5ʹ-CCA UGU GGA UAA AGU UGA Att-3ʹ (sense), 5ʹ-UUC AAC UUU AUC
CAC AUG Gtt-3ʹ (antisense); (2) 5ʹ-GAU GGU UCU UGC CUA CAA Att-3ʹ (sense), 5ʹUUUGUA GGC AAG AAC CAU Ctt-3ʹ (antisense); (3) 5ʹ-GCA AGA AUA GAC UCG
UAU Att-3ʹ (sense), 5ʹ-AUA ACG AGU CUA UUC UUG Ctt-3ʹ (antisense). Following
experimental procedures, culture medium was collected and stored at -20oC for VEGF
ELISA, or cells were harvested and prepared for qRT-PCR, western blot, or
immunofluorescence staining. Samples from at least three to four cell passages per
experimental group were collected.
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2.2 VEGF-A ELISA
VEGF-A release in treated INS-1 cell cultures was detected using a Rat VEGF Mini
ELISA Development Kit (PeproTech Canada; Dollard Des Ormeaux, QC, Canada)
according to manufacturer instructions. A total of 50 μg antigen-affinity purified
polyclonal rabbit anti-rat VEGF capture antibody with D-mannitol was diluted in 0.5 mL
of sterile water to a concentration of 100 μg/mL, then diluted in 1x PBS to a
concentration of 0.5 μg/mL. 100 μL was added to coat each well of an ELISA microplate
(Corning/VWR). The plate was sealed with manufacturer-provided sealing film, and
incubated at room temperature overnight. Wells were aspirated and washed four times
with 300 μL of wash buffer, containing 0.05% Tween-20 (Sigma) in 1x PBS, then the
plate was inverted to remove residual buffer. 300 μL of blocking buffer containing 1%
BSA (Sigma) in 1x PBS was added to each well and incubated for 1 hour at room
temperature, followed by aspiration and four more washes, as described previously. The
rat VEGF standard (PeproTech Canada), containing 1 μg of recombinant Rat VEGF, 2.2
mg of BSA, and 11.0 mg of D-mannitol, was diluted into 1 mL of sterile water, and
serially diluted in dilutent solution (0.05% Tween-20 [Sigma], 0.1% BSA [Sigma] in 1x
PBS) into varying concentrations, ranging from 2 ng/mL to zero. 100 μL of standard or
thawed treated INS-1 cell medium sample was added to each well in triplicate and
incubated at room temperature for 2 hours. 50 μg of biotinylated antigen-affinity purified
rabbit anti-rat VEGF detection antibody with 2.5 mg of D-mannitol (PeproTech Canada)
was diluted in 0.5 mL of sterile water to a concentration of 100 μg/mL. The solution was
diluted again in dilutent solution to a concentration of 0.5 μg/mL. 100 μL was added, per
well, and incubated at room temperature for 2 hours. Wells were aspirated and washed
four times, as described previously, and 100 μL of dilute Avidin-HRP conjugate
(1:2000)(# A-7419; Sigma) was added, per well, and incubated for 30 minutes at room
temperature. Wells were aspirated and washed four times, then 100 μL of ABTS Liquid
Substrate Solution (# A3219; Sigma) was added to each well, and incubated at room
temperature for colour development. Readings were taken with Multiskan spectrum
spectrophotometer (Thermo Scientific; Vantaa, Finland) at 405 nm with wavelength
correction set to 650 nm. Data are expressed as rat VEGF content in pg/mL.
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2.3 mRNA Extraction and qRT-PCR Analysis
To quantify relative gene expression levels of Hif-1α and Vegf-A in INS-1 cells following
SCF [50 ng/mL] treatment or c-Kit (r) siRNA-mediated knockdown, mRNA was
extracted from INS-1 cells cultured in 12-well culture plates (Fisher Scientific), 24 hours
following SCF treatment, or 48 hours following c-Kit (r) siRNA-mediated knockdown,
using a RNAqueous-4PCR kit (Invitrogen), according to manufacturer’s instructions
(Wang et al., 2005; Krishnamurthy et al., 2007). To verify RNA quality, 1% agarose gel
electrophoresis using ethidium bromide staining was performed for 18S and 28S
ribosomal subunits, and images were captured under UV light.
For each RT reaction, 2 μg of DNA-free RNA was heated at 60oC for 5 minutes, then
kept at 4oC for 10 minutes. Two microtubes per sample containing RNA with 1 μL
Oligo-(dT) primers, 2 μL of random hexamers/oligodeoxythymidine primers, and
diethylpyrocarbonate (DEPC) water were prepared added for a total volume of 10.5 μL
and an additional microtube containing no RNA was prepared, serving as a negative
control. Microtubes were vortexed and centrifuged briefly, then placed in the T-gradient
Biometra PCR thermal cycler (Montreal Biotech; Kirkland, QC, Canada) for 10 minutes
at 72oC and 5 minutes at 4oC. Microtubes were removed from the PCR machine, and
centrifuged briefly, then 8.5 μL of RT Master Mix (4.0 μL of 5x cDNA synthesis buffer,
2.0 μL of DTT, 2.0 μL of 10 mM dNTPs, 0.5 μL of Rnasin) and was added to each tube
and aspirated by pipette. A total of 0.8 μL of Superscript reverse transcriptase
(Invitrogen) was added to each tube and left to sit for 1 minute. Microtubes were put into
the PCR machine for 90 minutes at 42oC, 5 minutes at 94oC, and 60 minutes at 4oC. The
tubes were put on ice and samples were collected, together, into a new tube with an equal
amount of ddH2O.
For qRT-PCR, 1 μL of sample cDNA was loaded into PCR tubes (Low Tube Strips;
BioRad Laboratories) along with 5 μL of iQ SYBR Green Supermix (BioRad
Laboratories), 3 μL of sterile H2O, 0.5 μL of appropriate forward primer, and 0.5 μL of
appropriate reverse primer. Negative controls were loaded by replacing primer amounts
with sterile H2O. PCR primers used included Vegf-A: F, 5ʹ-ACT GCC ATC CAA TCG
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AGA CC-3ʹ and R, 5ʹ-GAG GTT TGA TCC GCA TAA TC-3ʹ (183 bp); Hif-1α: F, 5ʹCTT GAA GAT GTC CCG TTG TA-3ʹ and R, 5ʹ-ACA TTG ACC ATA TCG CTG
TCC-3ʹ (314 bp); c-Kit: F, 5ʹ-AGC AAG AGT TAA CGA TTC CGG AG-3ʹ and R, 5ʹCCA GAA AGG TGT AAG TGC CTC CT-3ʹ (344 bp); and 18S: F, 5ʹ-GTA ACC CGT
TGA ACC CCA TTC-3ʹ and R, 5ʹ-CCA TCC AAT CGG TAG TAG CG-3ʹ (151 bp).
Tubes were analyzed in Chromo4 Real Time PCR (BioRad Laboratories), with at least
three repeats per experimental group. Relative gene expression was determined by the
arithmetic formula “2-ΔΔCt” (Wang et al., 2005; Feng et al., 2013). Data was normalized
to the internal gene, 18S rRNA, while controls were established by a lack of amplified
fragments following omission of reverse transcriptase, cDNA, or DNA polymerase.

2.4 Protein Extraction and Western Blot Analysis
At the end of culture, media was aspirated and INS-1 cells were washed with 1x PBS.
Cells were then harvested and incubated in Nonidet-P40 lysis buffer (Nonidet-40,
phenylmethylsulfonyl fluoride, sodium orthovanadate [Sigma]; complete inhibitor
cocktail tablet [Roche]) for 30 minutes on ice. Cells were dispersed by sonicating to
extract protein. Samples were centrifuged at 12,000 rpm for 20 minutes at 4oC, and
supernatant was collected and frozen at -80oC for protein assay and western blot analysis.
Protein concentration was measured by a protein assay with Bradford dye (BioRad
Laboratories; Mississauga, ON, Canada), with standards prepared from bovine serum
albumin (BSA) at concentrations of 0-0.5 mg/mL. 10 μL of each standard and 1 μL of
each sample solution was loaded into micro titer plate wells in duplicate and mixed with
the colorimetric dye. The plate was incubated at room temperature for 20 minutes, and
readings were performed at 595 nm by a Multiskan spectrum spectrophotometer (Thermo
Scientific). An equal amount (15 μg) of lysate protein samples, mixed with 6x sample
buffer, from experimental groups and controls were separated by 5 (proteins greater than
180 kDa), 7.5 (proteins 100-180 kDa) and 10% (proteins 20-100 kDa) sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)(Table 2.1). A constant voltage
(40V) was applied to samples in order to migrate them through the stacking gel, after
which voltage was increased (80V) as protein entered the resolving gel, until the dye
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front reached the bottom. Protein was then transferred to a nitrocellulose membrane by
electroelution with BioRad’s Transblot system using transfer buffer containing glycine
(192 mM), Tris (25 mM) and methanol (20% v/v), and transferred at a constant current
(250 mA) for 2.5 hours at 4oC on a stir-plate. To check protein transferring, a Ponceau S
stain was used, followed by washing in Tris buffer-saline (TBS) containing 0.1% Tween20 (TBST). Membranes were incubated in 5% non-fat dry milk with TBST overnight at
4oC to block non-specific binding. Membranes were then incubated with primary
antibodies at the appropriate dilution (Table 2.1) for 2 hours at room temperature, and
then incubated with goat anti-rabbit IgG or anti-mouse IgG horseradish peroxidiseconjugated secondary antibody at appropriate dilution (Table 2.1) for 1 hour at room
temperature.

Membranes were washed again in TBST after secondary antibody

incubation and treated with enhanced chemiluminescent (ECL) reagents for 1 minute
(Western Lightning® Plus–ECL, Perkin Elmer; Wellesley, MA, USA) to visualize
protein. Images of immunoreactive bands were acquired using the Versadock 5000MP
imaging system (Bio-Rad Laboratories Mississauga, ON, Canada) with Quantity One
software (Bio-Rad Laboratories; Mississauga, ON, Canada). Densitometric quantification
was performed using Image Lab 3.0 software (Bio-Rad Laboratories; Mississauga, ON,
Canada) and normalized to either total protein or a loading control (GAPDH).

2.5 Immunofluorescence Staining
Following harvesting, cells were fixed in 4% paraformaldehyde (PFA) (Fisher Scientific
Company; Ottawa, ON, Canada) overnight at 4oC, then embedded in 2% agarose gel, and
processed into paraffin blocks (Wu et al., 2010), using an automated tissue processing
and embedding machine (Shandon CitadelTM Tissue Processor, Citadel 1000, Thermo
Electron Corporation; Waltham, MA, USA). Blocks were cut into sections using a
microtome (Leica RM2245, Vashaw Scientific Inc.; Nocross, Atlanta, USA) onto glass
slides (Fisher Scientific).
Mounted samples were allowed to incubate at 37oC overnight, after which, they were
deparaffinised by xylene for 10-minutes three times, and rehydrated with ethanol of
varying concentrations, starting with 100% and concluding with 70%. Following
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rehydration, slides were rinsed with deionized water, followed by 1x PBS washing.
Nonspecific binding was blocked by applying 10% normal goat serum diluted in 1x PBS
for 30 minutes at room temperature in a humidified container. Primary antibodies at
appropriate dilutions, as listed in Table 2.2, were applied to sample sections and
distributed evenly by application of a cover slip (Fisher Scientific). Sections were
incubated overnight at 4oC in a humidified container. Following incubation with primary
antibody, cover slips were removed and sections were rinsed with DI water, followed by
1x PBS. Appropriate dilutions of secondary antibodies conjugated with either fluorescein
isothiocyanate (FITC) or tetramethyl rhodamine isothiocyanate (TRITC)(Jackson
Immunoresearch Laboratories; West Grove, PA, USA) (Table 2.2) were applied to
sections and distributed evenly by application of a cover slip (Fisher Scientific). Sections
were left to incubate for 1 hr at room temperature within a humidified container.
Following incubation, cover slips were removed, and sections were rinsed with DI water,
followed by 1x PBS. Cell nuclei were counterstained with 4’-6’-diamidino-2-phenylindol
(DAPI) (Sigma) for 5 minutes at room temperature within a humidified container, then
rinsed in 1x PBS. Cover slips were adhered to slides by fluorescence mounting medium
(Dako; Burlington, ON, Canada). Negative controls were obtained by omission of
primary and secondary antibodies.

2.6 Morphometric Analyses
Sections were viewed through a Leica DMIRE 2 fluorescence microscope (Leica
Microsystems; Bannockburn, IL, USA) and images were taken with a digital camera
(Retiga 1300, High-sensitivity IEEE 1394 FireWireTM digital camera, QIMAGING;
Burnaby, BC, Canada). Images were stored on a Windows computer, analyzed by
ImagePro Plus imaging software (Media Cybernetics Inc; Rockville, MD, USA). The
percentage of VEGF-A positive signaling in insulin-positive or insulin-negative cells, or
insulin-positive with no VEGF-A staining was determined by cell counting. A minimum
of 1000 cells per section per experimental group, with a minimum of three repeat
experiments per group were counted. Co-localization of VEGF-A and insulin was
determined as a percentage of total cells appearing in the section, characterized by DAPI
counterstaining.
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2.7 Statistical Analysis
Data are expressed as means ± SD. Statistical significance was determined by either
unpaired Student’s t-test or one-way ANOVA with the post-hoc Fisher’s least significant
difference (LSD) test. Differences were considered statistically significant when p < 0.05.
GraphPad Prism 6 (GraphPad Software; La Jolla, CA, USA) was used to conduct
analyses.
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Table 2.1 List of antibodies used for western blotting
Primary Antibody
Mouse anti-phosphorylated Akt (Ser 473)
Rabbit anti-Akt
Rabbit anti-phosphorylated GSK3β (Ser 9)
Rabbit anti-GSK3β
Rabbit anti-VEGF
Rabbit anti-β-catenin
Rabbit anti-phosphorylated ErK1/2
(Thr202/Tyr204)
Rabbit anti-ErK1/2
Rabbit anti-phosphorylated mTOR (Ser 2448)
Rabbit anti-mTOR
Rabbit anti-phosphorylated NFκBp65 (Ser536)
Rabbit anti-NFκBp65
Rabbit anti-phosphorylated P38 MAPK
(Thy180/Tyr182)
Rabbit anti-P38 MAPK
Mouse anti-phosphorylated P70S6K (Thr389)
Rabbit anti-P70S6K
Rabbit anti-phosphorylated c-Kit (Tyr719)
Rabbit anti-c-Kit

Rabbit anti-GAPDH
Secondary Antibody
HRP-conjugated Goat anti-mouse
HRP-conjugated Goat anti-rabbit
HRP-conjugated Goat anti-rat

Dilution Company; Location
Cell Signaling;
1:2000 Danvers, MA, USA
Cell Signaling;
1:3000 Danvers, MA, USA
Cell Signaling;
1:2000 Danvers, MA, USA
Cell Signaling;
1:2000 Danvers, MA, USA
Abcam; Cambridge,
1:2000 MA, USA
Millipore; Billerica,
1:1000 CA, USA
Cell Signaling;
1:3000 Danvers, MA, USA
Cell Signaling;
1:5000 Danvers, MA, USA
Cell Signaling;
1:1000 Danvers, MA, USA
Cell Signaling;
1:1000 Danvers, MA, USA
Cell Signaling;
1:1000 Danvers, MA, USA
Cell Signaling;
1:1000 Danvers, MA, USA
Cell Signaling;
1:1000 Danvers, MA, USA
Cell Signaling;
1:1000 Danvers, MA, USA
Cell Signaling;
1:1000 Danvers, MA, USA
Cell Signaling;
1:1000 Danvers, MA, USA
Cell Signaling;
1:1000 Danvers, MA, USA
Abcam; Cambridge,
1:500 MA, USA
Santa Cruz
Biotechnologies; Santa
1:2000 Cruz, CA, USA
Dilution Company; Location
Cell Signaling;
1:2000 Danvers, MA, USA
Cell Signaling;
1:2000 Danvers, MA, USA
Abcam; Cambridge,
1:2000 MA, USA

Molecular
Weight
60 kDa
60 kDa
46 kDa
46 kDa
43 kDa
92 kDa
42, 44 kDa
42, 44 kDa
289 kDa
289 kDa
65 kDa
65 kDa
40 kDa
40 kDa
65 kDa
70 kDa
120 kDa
107 kDa

37 kDa
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Table 2.2 List of antibodies used for immunofluorescence
Primary Antibody
Guinea pig anti-insulin
Mouse anti-VEGF
Rabbit anti-c-Kit
Secondary Antibody
Cy2/3 conj. Goat antirabbit
Cy2/3 conj. Goat antimouse
Cy3 conj. Goat antiguinea pig

Dilution
1:50
1:50
1:100
Dilution

Company; Location
Zymed Laboratories; San Francisco, CA, USA
Santa Cruz Biotechnologies; Santa Cruz, CA, USA
Abcam; Cambridge, MA, USA
Company; Location

1:50 Jackson Immunoresearch; West Grove, PA, USA
1:50 Jackson Immunoresearch; West Grove, PA, USA
1:50 Jackson Immunoresearch; West Grove, PA, USA
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Chapter 3

3

Results

3.1 c-Kit and VEGF-A co-localization in INS-1 Cells
To examine whether SCF/c-Kit interaction regulates VEGF-A production, co-expression
of c-Kit and VEGF-A was analyzed. In order to clearly reveal the co-localization, we
cultured INS-1 cells in serum-free medium containing 50 ng/mL SCF for 24 h. Cells
were harvested and co-stained by double-immunofluorescence for c-Kit and VEGF-A. cKit-positive signals were observed near the cell membrane, while VEGF-A was found
primarily in the cytoplasm of INS-1 cells (Figure 3.1).

3.2 Determining Sufficient Dosage and Time-points for VEGF-A
Secretory Action in INS-1 cells
To examine the ramifications of exogenous SCF-stimulated c-Kit activation on VEGF-A
release in vitro, an optimal dosage and time at which c-Kit signaling exerts a quantifiable
effect on secreted VEGF-A was established. SCF stimulation at concentrations of 10, 20,
30, 50 and 100 ng/mL after 24 h in the INS-1 cell line (Baghestanian, 1997; Chung et al.,
2003; Ren et al., 2003; Feng et al., 2013) were first examined. VEGF-A accumulation in
culture medium was assessed at each dose by a rat VEGF mini ELISA development kit,
and showed no change in VEGF-A release when the cells treated with 10 and 20 ng/mL
of SCF, but release began to increase at 30 ng/mL (p < 0.01, Figure 3.2). Cells treated
with 50 ng/mL of SCF showed a further increase in VEGF-A release when compared to
controls, reaching a plateau at 100 ng/mL (p < 0.001, Figure 3.2). This suggests that 50
ng/mL at 24 hours was sufficient to elicit significant VEGF-A release response. To
examine the time-dependent effect of SCF/c-Kit signaling on VEGF-A production, we
treated INS-1 cells with SCF at a 50 ng/mL dosage for either 1, 6 or 24 hours followed by
examination of VEGF-A release by ELISA. There were slight increases of VEGF-A
levels in the culture medium at 1 hour, reaching statistical significance at 6 hours (p <
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0.05, Figure 3.3), with greater significance at 24 hours of culture, when compared to
time-matched controls (p < 0.01, Figure 3.3).

3.3 Expression of Hif-1α and Vegf-A mRNA and VEGF-A
Protein in INS-1 Cells Following SCF Treatment
After establishing an optimal dose (50 ng/mL) at 24 h of SCF treatment in INS-1 cells,
we examined changes in VEGF-A mRNA and protein levels. At the mRNA level, there
was a significant increase in Hif-1 and Vegf-A mRNA levels 24 h following 50 ng/mL
SCF treatment (p < 0.05, Figure 3.4A). Western blot analysis of VEGF-A protein levels
in INS-1 cells showed a ~25% increase in VEGF-A protein levels in the SCF-treated
group compared to controls, but did not reach statistical significance (Figure 3.4B).

3.4 Increased numbers of VEGF-A and Insulin Double-positive
cells following SCF Treatment
Double immunofluorescence staining was performed to examine the co-expression
pattern of VEGF-A and insulin in INS-1 cells 24 h following 50 ng/mL SCF treatment
(Figure 3.5A). Increased numbers of VEGF-A and insulin double positive cells in the
SCF-treated group (89.2 ± 0.5%) were observed compared to the control group (85.0 ±
1.5%) (p < 0.01, Figure 3.5B). However, the numbers of VEGF-A positive with no
insulin staining (VEGF-A+ Insulin-) cells were reduced in SCF-treated cells (8.4 ± 0.5%)
compared to controls (10.7 ± 0.9%) (p < 0.05, Figure 3.5C). Similarly, observation
showed that insulin-positive cell populations without VEGF-A (VEGF-A- Insulin+) were
reduced in SCF-treated groups (2.5 ± 0.3%) compared to controls (4.3 ± 0.6%) (p < 0.01,
Figure 3.5C). It is possible that, since this cell line has a high rate of proliferation, cells
lacking insulin were in an early phase of growth, and had not yet acquired an insulinproducing phenotype.
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Figure 3.1 Co-localization of c-Kit and VEGF-A in INS-1cells.
Double immunofluorescence staining for c-Kit (green) with VEGF-A (red) in INS-1
cells cultured in serum-free medium plus 50 ng/mL SCF treatment for 24 h, shows colocalization of c-Kit with VEGF-A. A representative image of live cell staining on the
coverslips is shown and bottom panel shows magnified images each corresponding to
the section within the square. Nuclei were stained with DAPI (blue); scale bar: 10 μm.
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Figure 3.2 Comparison of VEGF-A secretion of INS-1 cells treated with varying
concentrations of SCF for 24 h.
INS-1 cells were cultured in 12-well plates and treated with varying concentrations of
recombinant SCF [0, 10, 20, 30, 50, 100 ng/mL] for 24 hours to observe a dose-dependent
VEGF-A secretory response. Culture medium was collected and analyzed for VEGF-A
secretion. The Rat VEGF mini ELISA kit was used to quantify data. Data are expressed
aspictograms per milliliter in means ± SD (n=4; ** p < 0.01, *** p < 0.001vs. 0 ng/mL group
determined by one-way ANOVA with Fisher’s Least Significant Difference post-hoc test).
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Figure 3.3 Comparison of VEGF-A accumulation in INS-1 cell culture medium
following treatment with recombinant SCF for varying time-points.
INS-1 cells were cultured in 12-well plates and treated with recombinant SCF at a
concentration of 50 ng/mL, determined to be sufficient in eliciting a VEGF-A secretory
response, at time points of 1h, 6h, and 24 h. Culture medium was collected at all timepoints, along with culture medium of untreated time-matched controls, and analyzed for
VEGF-A content with the Rat VEGF mini ELISA kit. Data are expressed aspictograms per
milliliter in means ± SD (n=4; **p < 0.01, ***p < 0.001 vs. control group determined by
one-way ANOVA with Fisher’s Least Significant Difference post-hoc test).
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Figure 3.4 The mRNA levels of Hif-1α and Vegf-A, total protein level of VEGF-A
incultured INS-1 cells following SCF treatment.
INS-1 cells were cultured in 12-well plates containing RPMI-1640 1% BSA medium
overnight, and treated with human recombinant SCF at a concentration of 50 ng/mL for
24 hours. RNA and protein were harvested analyzed. (A) qRT-PCR analysis of total
Vegf-A and Hif-1α mRNA levels in untreated controls and SCF-treated groups. Extracted
RNA was purified by the RNAqueous-4PCR kit and analyzed using the iQ SYBR Green
Supermix kit. Data are expressed as means ± SD (n=4; *p < 0.05 vs. controls determined
by unpaired Student’s t-test) (B) Western blot analysis of VEGF-A protein level
comparison between untreated controls and SCF-treated groups, normalized to GAPDH.
Data are expressed as means ± SD (n=3).
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Figure 3.5 The number of VEGF-A+ and insulin+ cells in SCF-treated INS-1 cells.
INS-1 cells were cultured in 12-well plates containing RPMI-1640 1% BSA medium
overnight, and treated with human recombinant SCF at a concentration of 50 ng/mL for
24 hours. Cells were harvested and fixed in 4% paraformaldehyde (PFA), then embedded
in 2% agarose gel, and processed into paraffin blocks, which were then cut into sections
with a microtome onto glass slides. Sections were then immunolabeled with anti-VEGFA (Cy2, green) and anti-insulin (Cy3, red). Nuclei were labeled with with 4’,6-diamidino2—phenylindole (DAPI, blue). (A) Representative images for VEGF-A and insulin colocalization are shown. Scale bar: 5 μm. (B) Morphometric analysis of the total number
of INS-1 cells co-expressing VEGF-A and insulin 24 h following treatment by SCF [50
ng/mL]. Data are expressed as percentage of counted cells in means ± SD (n=3; ** p <
0.01 vs. controls determined by unpaired Student’s t-test). (C) Morphometric analysis of
total number of INS-1 cells positive for VEGF-A and negative for insulin (left), and total
number of INS-1 cells negative for VEGF-A and positive for insulin. Data are expressed
as means ± SD (n=3; * p < 0.05, ** p < 0.01vs. controls determined by unpaired
Student’s t-test).
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3.5 SCF/c-Kit Regulation of VEGF-A Production is Associated
with PI3K/Akt/mTOR and Gsk3β/β-catenin Signaling
To investigate which intracellular signaling pathways are involved in regulating VEGF-A
production, we examined signaling molecules downstream of c-Kit. INS-1 cells treated
with 50 ng/mL SCF for 24 h showed significantly increased phosphorylation of c-Kit at
tyrosine residue 719 when compared to controls (p < 0.05, Figure 3.6A). The
PI3K/Akt/mTOR axis downstream of c-Kit was examined and it was found that levels of
Akt phosphorylated at serine residue 473 were significantly increased in the SCF-treated
cells compared to controls (p < 0.01, Figure 3.6B), and levels of mTOR phosphorylated
at serine residue 2448 were also significantly increased in the SCF-treated cells, (p <
0.01, Figure 3.7A). mTOR activation was further confirmed by determining
phosphorylation of its target, P70S6K, at threonine residue 389, which also exhibited
increased activation when compared to controls (p < 0.05, Figure 3.7B). Activation of
mTOR has been linked to activation of a variety of transcription factors, including
NfκBp65 (Dan et al., 2008; Radhakrishnan et al., 2013). NfκBp65 itself has been
implicated in the progression of a variety of cancers by its involvement in stimulation of
angiogenic processes and, specifically, VEGF regulation at the mRNA level (Leibovich
et al., 2002; Shibata et al., 2002). Thus, phosphorylation of NfκBp65 at serine residue
536 was assessed and shown to be significantly increased in SCF-treated groups, when
compared to controls (p < 0.05, Figure 3.7C). These data demonstrate that exogenous
SCF stimulation of c-Kit activation, results in activation of the PI3K/Akt/mTOR
signaling pathway.
Previous studies in our laboratory showed that activation of c-Kit in β-cells leads to an
increase in Gsk3β phosphorylation at serine residue 9 (Feng et al., 2012). Inactivating
Gsk3β by phosphorylation allows for increased activation of β-catenin, a known
inhibitory target of Gsk3β and a molecule with several consensus binding sites for the
gene promoter of VEGF-A (Easwaran et al., 2003; Skurk et al., 2005). Gsk3β
phosphorylation was assessed and, in comparison to controls, exhibited an increased level
of phosphorylation following SCF stimulation (p < 0.01, Figure 3.8A). Total β-catenin
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levels were also found to be significantly more abundant in SCF-treated group (p < 0.05,
Figure 3.8B). These results suggest that SCF/c-Kit interactions increase Akt activation,
leading to inactivation of Gsk3β and an increase in biologically active β-catenin, which is
able to interact with VEGF promoters to produce VEGF-A. Taken together, these results
suggest that, by targets downstream of the PI3K/Akt/mTOR pathway, SCF-mediated cKit activation resulted in increased production of VEGF-A.

3.6 SCF/c-Kit-mediated VEGF-A Production via Activation of
Alternative Pathways
c-Kit activation has been found to stimulate increased activation of other pathways that
converge onto the PI3K/Akt/mTOR axis and are able to synergistically enhance the
downstream effects of this pathway (Ronnstrand, 2004). Two proteins in the MAPK
signaling pathway, p38 and p44/42, are thought to be involved as a result of SCF/c-Kit
interactions. Thus, we aimed to investigate whether this pathway might impose
convergent action on stimulating VEGF production (Jin et al., 2005; Kuang et al., 2008).
There was no change in p44/42 phosphorylation (Figure 3.9A), but levels of
phosphorylated p38 at tyrosine residues 180 and 182 were increased in the SCF-treated
group (p < 0.05, Figure 3.9B). These results suggest that activation of MAPK/p38
converges on targets in the PI3K/Akt/mTOR pathway, possibly eliciting synergistic
stimulation of VEGF-A production.

3.7 Pharmacological Inhibition of PI3K and mTOR Attenuated
the Release of VEGF-A Following SCF Treatment
To further demonstrate that VEGF-A production and release are dependent on the
PI3K/Akt/mTOR pathway, VEGF-A release was measured following treatment with a
combination of SCF 50 ng/mL, and various dosages of the PI3K inhibitor, Lys294002 (0100 μmol/L), or the mTOR inhibitor, rapamycin (0-100 nmol/L). It was noted that INS-1
cells treated with Lys294002 or rapamycin at different dosages for 24 h showed no effect
on cell loss (Appendix I), however, VEGF-A levels in culture medium were altered in a
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dose-dependent fashion (Figure 3.10, 3.11). It was found that enhanced VEGF-A release
stimulated by treatment with 50 ng/mL SCF was abolished when 10 μmol/L of
Lys294002 was added (Figure 3.10C). Similarly, SCF-stimulated VEGF-A release was
abolished when cells were treated with rapamycin at dosage of 20 nmol/L (Figure
3.11C). These results further verify that, despite SCF-stimulated activation of c-Kit, the
inhibition of key targets along the PI3K/Akt/mTOR pathway resulted in a loss of VEGFA accumulation in culture medium and, thus, SCF/c-Kit downstream PI3K/Akt/mTOR
pathways are responsible for regulating VEGF-A production.

3.8 Knockdown of c-Kit Expression in the INS-1 Cell Line by cKit siRNA Transfection
INS-1 cells were transiently transfected with either c-Kit (r) siRNA or control siRNA to
examine the effect of c-Kit down-regulation on VEGF-A production. Following siRNA
treatment for 48 to 72 hours, the expression of c-Kit mRNA, protein and phosphorylation
were determined. Following 48 h of transfection culture, c-Kit mRNA expression was
reduced ~45%, as determined by qRT-PCR, but did not reach statistical significance
(Figure 3.12A). There was a significant decrease in the amount of total c-Kit protein
after 72 h of c-Kit (r) siRNA-transfection in INS-1 cells compared to those treated with
control siRNA (p < 0.05, Figure 3.12B). We further examined the levels of phosphor-cKit at 72 h of c-Kit(r) siRNA-transfected cells and observed a reduction in c-Kit
activation (Figure 3.12C). These data verified that siRNA treatment mediated c-Kit
knockdown at both the mRNA and protein level, allowing for analysis of further
downstream targets.

3.9 Expression of VEGF-A Production in INS-1 Cells Following
siRNA-mediated c-Kit Knockdown
Forty-eight hours following c-Kit (r) siRNA-mediated knockdown in INS-1 cells, levels
of Hif-1α and Vegf-A mRNA were assessed by qRT-PCR analysis. It was found that
transcript levels of both Hif-1α and Vegf-A trended toward a decrease, though did not
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reach significance (Figure 3.13A). After 72 hours of transfection, western blot analysis
of intracellular VEGF-A content was reduced ~21% in the c-Kit (r) siRNA-treated group
compared to control siRNA group, though was not significantly different (Figure 3.13B).
VEGF-A release into the culture medium, analyzed by a rat VEGF mini ELISA kit,
showed non-significant, minimal reduction compared to controls (Figure 3.13C),
indicating that down-regulation of c-Kit expression by siRNA affects VEGF-A
production. We further examined the number of VEGF-A-positive and insulin-positive
cells in both experimental groups and found neither double-positive cell nor singlepositive cell populations had changed (Figure 3.14).

3.10 Knockdown of c-Kit Inhibits the PI3K/Akt/mTOR Signaling
Pathway
The downstream PI3K/Akt/mTOR axis was assessed in order to confirm down-regulation
of signaling molecules downstream of c-Kit after a 72 h c-Kit siRNA transfection. Levels
of Akt phosphorylated at serine residue 473 were significantly decreased in the
knockdown cells, compared to controls (p < 0.05, Figure 3.15A), and levels of mTOR
phosphorylated at serine residue 2448 were also significantly decreased in the c-Kit
siRNA knockdown cells, compared to controls (p < 0.05, Figure 3.15B). mTOR
activation was further confirmed by assaying phosphorylation of its well-established
target, P70S6K, at threonine residue 389, which also exhibited decreased activation when
compared to controls (p < 0.01, Figure 3.15C). Phosphorylation of NfκBp65 at serine
residue 536 was found to be significantly decreased in c-Kit knockdown groups, when
compared to controls (p < 0.05, Figure 3.15D). These analyses confirmed that
knockdown of c-Kit expression resulted in decreased activation of molecules along the
PI3K/Akt/mTOR pathway.
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3.11 Inactivation of Downstream Targets of Akt and p38 inhibit
VEGF-A Production and Release
Further signaling molecules downstream of the PI3K/Akt pathway were examined in
order to provide a linkage specifically to decreased VEGF-A production in these cells,
due to knockdown of c-Kit by siRNA transfection. Gsk3β phosphorylation was
decreased, suggesting that its activation was increased, following knockdown of c-Kit
compared to controls (p < 0.05, Figure 3.16A). Upon analysis, total β-catenin levels were
shown to decrease significantly in abundance in the knockdown groups (p < 0.05, Figure
3.16B). As mentioned in section 3.8, p38 MAPK is thought to work synergistically to
activate mTOR alongside the PI3K/Akt pathway and, ultimately, increase VEGF-A
production. In the case of siRNA-mediated knockdown, it was found that p38 MAPK
protein levels trended toward decrease, but did not reach significance (Figure 3.16C).
Taken together, these results suggest that by inhibition of targets downstream of the
PI3K/Akt/mTOR pathway, c-Kit knockdown results in the decreased production of
VEGF-A.
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Figure 3.6 Protein analysis of c-Kit and Akt activation in cultured INS-1 cells treated
with SCF.
INS-1 (832/13) cells were cultured in 12-well plates containing RPMI-1640 1% BSA
medium overnight, and treated with human recombinant SCF at a concentration of 50
ng/mL for 24 hours. Cells were incubated in Nonidet-P40 lysis buffer and dispersed by
sonication to extract protein. c-Kit and Akt phosphorylation was compared by western blot
analysis, with representative images of western blots shown on top of graphs. Proteins
assayed include (A) Phosphorylated (Tyr719) c-Kit compared to total c-Kit, (B)
phosphorylated (Ser473) Akt compared to total Akt. Data are normalized to total protein
levels and expressed as fold versus control (means ± SD; n=3-4; * p < 0.05, ** p < 0.01 vs.
controls analyzed by unpaired Student’s t-test).
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Figure 3.7 Protein analysis of mTOR activation and its downstream targets, P70S6K
and NfκBp65 in cultured INS-1 cells treated with SCF.
INS-1 cells were cultured in 12-well plates containing RPMI-1640 1% BSA medium
overnight, and treated with human recombinant SCF at a concentration of 50 ng/mL for 24
hours. Cells were incubated in Nonidet-P40 lysis buffer and dispersed by sonication to extract
protein. mTOR, P70S6K and NfκB phosphorylation was compared by western blot analysis,
with representative images of western blots shown on top of graphs. Proteins assayed include
(A) Phosphorylated (Ser2448) mTOR compared to total mTOR, (B) phosphorylated (Thr389)
p70S6K compared to total p70S6K, (C) phosphorylated (Ser536) NfκBp65 compared to total
NfκBp65. Data are normalized to total protein levels and expressed as fold versus control
(means ± SD; n=3-4; * p < 0.05, ** p < 0.01 vs. controls analyzed by unpaired Student’s ttest).
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Figure 3.8 Protein analysis of activated Gsk3β and total β-catenin in cultured INS-1
cells treated with SCF.
INS-1 (832/13) cells were cultured in 12-well plates containing RPMI-1640 1% BSA
medium overnight, and treated with human recombinant SCF at a concentration of 50 ng/mL
for 24 hours. Cells were incubated in Nonidet-P40 lysis buffer and dispersed by sonication to
extract protein. Gsk3β phosphorylation and total β-catenin were compared by western blot
analysis, with representative images of western blots shown on top of graphs. Proteins
assayed include (A) phosphorylated (Ser9) Gsk3β compared to total Gsk3β, (B) total βcatenin compared to housekeeping protein GAPDH. Data are normalized to total protein
levels or GAPDH and expressed as fold versus control (means ± SD; n=3-4; * p < 0.05, ** p
< 0.01 vs. controls analyzed by unpaired Student’s t-test).
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Figure 3.9 Protein analysis of activated p42/44 MAPK and p38 MAPK in cultured INS-1
cells treated with SCF.
INS-1 cells were cultured in 12-well plates containing RPMI-1640 1% BSA medium
overnight, and treated with human recombinant SCF at a concentration of 50 ng/mL for 24
hours. Cells were incubated in Nonidet-P40 lysis buffer and dispersed by sonication to extract
protein. p42/44 MAPK and p38 MAPK phosphorylation was compared by western blot
analysis, with representative images of western blots shown on top of graphs. Proteins assayed
include (A) phosphorylated (Thr202/Tyr204) p42/44 MAPK compared to total p42/44 MAPK
(B) phosphorylated (Thr180/Tyr182) p38 MAPK compared to total p38 MAPK. Data are
normalized to total protein levels and expressed as fold versus control (means ± SD; n=3-4; * p
< 0.05vs. controls analyzed by unpaired Student’s t-test).
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Figure 3.10 VEGF-A secretion in SCF-treated cultured INS-1 cells with and
without varying concentrations of a PI3K inhibitor (Lys294002).
INS-1 cells were cultured in 12-well plates containing RPMI-1640 1% BSA medium
overnight. Fresh medium was added to wells, and cells were cultured with Lys294002 in
increasing concentrations [0, 1, 10, 100 umol/L], with human recombinant SCF [50
ng/mL] or an SCF vehicle for a period of 24 h. At the end of the culture period, culture
medium was collected and analyzed for VEGF-A secretion. VEGF-A secretion analyses
are shown for (A) control and SCF-treated, (B) Lys294002 1 umol/L with or without
SCF, (C) Lys294002 10 umol/L with or without SCF, (D) Lys294002 100 umol/L with
or without SCF. The Rat VEGF mini ELISA kit was used to quantify data. Data are
normalized to total protein levels and expressed as fold versus control (means ± SD;
n=3;** p < 0.01 SCF vs control determined by unpaired Student’s t-test).
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Figure 3.11 VEGF-A release in untreated and SCF-treated cultured INS-1 cells with
and without varying concentrations of an mTOR inhibitor (rapamycin).
INS-1 cells were cultured in 12-well plates containing RPMI-1640 1% BSA medium
overnight. Fresh medium was added to wells, and cells were pre-treated with increasing
concentrations of rapamycin [0, 5, 20, 100 nmol/L] for 30 minutes prior to treatment with
either human recombinant SCF [50 ng/mL] or an SCF vehicle for a period of 24 hours.
At the end of the culture period, cell medium was collected and analyzed for VEGF-A
secretion. VEGF-A secretion analyses are shown for (A) control and SCF-treated, (B)
rapamycin 5 nmol/L with and without SCF, (C) rapamycin 20 nmol/L with and without
SCF, (D) rapamycin 100 nmol/L with and without SCF. The Rat VEGF mini ELISA kit
was used to quantify data. Data are expressed as means ± SD (n=3; * p < 0.05, *** p <
0.001 SCF vs. control determined by unpaired Student’s t-test).
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Figure 3.12 c-Kit expression in cultured INS-1 cells following siRNA-mediated c-Kit
knockdown.
INS-1 cells were cultured on 12-well plates and treated with either c-Kit (r) siRNA or control
siRNA transfection mixtures. Transient transfection took place for either 48 h or 72 h. mRNA
was harvested from cells after 48 h of transient transfection with the RNAqueous-4PCR kit.
(A) RT-PCR images showed expression of c-Kit and 18S captured under UV light and qRTPCR analysis of c-Kit mRNA at 48 h of culture. Data are expressed as fold-change vs. control
siRNA group (n=3). Following 72 h of transient transfection, cells were incubated in NonidetP40 lysis buffer and dispersed by sonication to extract protein. Extracted protein was analyzed
from both groups by western blot analysis, with representative images of western blots shown
on top of graphs. (B) Total c-Kit levels were normalized to housekeeping protein GAPDH, (C)
Phosphorylated (Tyr 719) c-Kit levels were normalized to housekeeping protein GAPDH. Data
are expressed as fold versus control (means ± SD; n=3; * p < 0.05, ** p < 0.01 vs. control
siRNA group determined by unpaired Student’s t-test).
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Figure 3.13 Total mRNA levels of Hif-1α and Vegf-A, protein level of VEGF-A, and
VEGF-A secretion of cultured INS-1 cells following c-Kit siRNA treatment.
INS-1 cells were cultured in 12-well plates containing RPMI-1640 10% FBS medium
overnight, and treated with either c-Kit (r) siRNA or control siRNA for 48 h or 72 h. RNA
was harvested at 48 h, while cellular protein and culture medium were were collected after
72 h and analyzed. (A) qRT-PCR analysis of total Vegf-A and Hif-1α mRNA levels in
controls and c-Kit siRNA-treated groups. Extracted RNA was purified by the RNAqueous4PCR kit and analyzed using the iQ SYBR Green Supermix kit. Data are expressed as
means ± SD (n=5) (B) Western blot analysis of VEGF-A protein level comparison
between controls and c-Kit siRNA-treated groups. Data are normalized to GAPDH and
expressed as fold versus control (means ± SD; n=3). (C) Analysis of VEGF-A secretion
into medium after 72 h of siRNA-mediated c-Kit knockdown. The Rat VEGF mini ELISA
kit was used to quantify data. Data are expressed as means ± SD (n=6).
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Figure 3.14 The number of VEGF-A+ and insulin+ cells in c-Kit siRNA and control
siRNA-treated INS-1 cells.
INS-1 cells were cultured in 12-well plates containing RPMI-1640 10% FBS medium
overnight, and treated with either c-Kit (r) siRNA or control siRNA for a period of 72 h.
Cells were harvested and fixed in 4% paraformaldehyde (PFA), then embedded in 2%
agarose gel, and processed into paraffin blocks, which were then cut into sections with a
microtome onto glass slides. Sections were then immunolabeled with anti-VEGF-A (Cy2,
green) and anti-insulin (Cy3, red). Nuclei were labeled with with 4’,6-diamidino-2—
phenylindole (DAPI, blue). (A) Representative images for VEGF-A and insulin colocalization are shown. Scale bar: 5 μm. (B) Morphometric analysis of the total number of
INS-1 cells co-expressing VEGF-A and insulin 72 h following treatment by c-Kit siRNA.
(C) Morphometric analysis of total number of INS-1 cells positive for VEGF-A and negative
for insulin (left), and total number of INS-1 cells negative for VEGF-A and positive for
insulin. Data are expressed as means ± SD (n=3).
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Figure 3.15 Protein analysis of Akt, mTOR, P70S6K, NfκBp65 activation in cultured
INS-1 cells treated with c-Kit siRNA.
INS-1 cells were cultured in 12-well plates containing RPMI-1640 10% FBS medium
overnight, and treated with either c-Kit (r) siRNA or control siRNA for 72 h. Cells were
incubated in Nonidet-P40 lysis buffer and dispersed by sonication to extract protein. Akt,
mTOR, P70S6K, and NfκBp65 phosphorylation was compared by western blot analysis, with
representative images of western blots shown on top of graphs. Proteins assayed include (A)
Phosphorylated (Ser473) Akt compared to total Akt, (B) phosphorylated (Ser2448) mTOR
compared to total mTOR, (C) phosphorylated (Thr389) P70S6K compared to total P70S6K,
(D) phosphorylated (Ser536) NfκBp65 compared to total NfκBp65. Data are normalized to
total protein levels and expressed as fold versus control (means ± SD; n=3-4; * p < 0.05, ** p
< 0.01 vs. control siRNA groups analyzed by unpaired Student’s t-test).
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Figure 3.16 Protein analysis of Gsk3β activation, total β-catenin, and p38 MAPK
activation in cultured INS-1 cells treated with c-Kit siRNA.
INS-1 cells were cultured in 12-well plates containing RPMI-1640 10% FBS medium
overnight, and treated with either c-Kit (r) siRNA or control siRNA for 72 h. Cells were
incubated in Nonidet-P40 lysis buffer and dispersed by sonication to extract protein. Gsk3β
phosphorylation, total levels of β-catenin, and phosphorylation of p38 MAPK was compared
by western blot analysis, with representative images of western blots shown on top of graphs.
Proteins assayed include (A) Phosphorylated (Ser9) Gsk3β compared to total Gsk3β, (B) total
β-catenin compared to housekeeping protein GAPDH, (C) phosphorylated (Thr180/Tyr182)
p38 MAPK compared to total p38 MAPK. Data are normalized to total protein levels or
GAPDH and expressed as fold versus control (means ± SD; n=3-4; * p < 0.05 vs. control
siRNA analyzed by unpaired Student’s t-test).
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Chapter 4

4

Discussion

The objective of this thesis was to investigate the functional role of c-Kit in the regulation
of β-cell VEGF-A production and associated intracellular signaling pathway using the
INS-1 cell line as an in vitro model. The hypothesis was that an increase in c-Kit
activation could stimulate VEGF-A production in β-cells via the PI3K/Akt/mTOR
pathway. The results presented in this study highlight that there is a significant increase
in VEGF-A release, a factor required for islet vessel formation, in INS-1 cells following
stimulation with exogenous SCF. This effect was mediated by upregulation of
phosphorylated c-Kit and its downstream targets along the PI3K/Akt/mTOR signaling
pathway. Cells treated with SCF plus either a PI3K inhibitor (Lys294002) or mTOR
inhibitor (rapamycin) displayed an attenuation in VEGF-A levels in culture medium,
providing further evidence that activation of c-Kit and its downstream PI3K/Akt/mTOR
signaling pathway is essential for VEGF-A modulation (Figure 4.1). Conversely, INS-1
cells treated with c-Kit siRNA demonstrated that knockdown of c-Kit expression results
in a decrease of phosphorylation along the Akt/mTOR pathway and, consequently,
decreased production and release of VEGF-A. Taken together, these findings lay down
the groundwork suggesting that the c-Kit receptor tyrosine kinase and downstream targets
of the PI3K/Akt/mTOR axis exert a regulatory effect on VEGF-A production and release
in β-cells in vitro. Further investigation of c-Kit-mediated VEGF-A production and
function using exogenous SCF to stimulate isolated murine islets, and in vivo models
with transgenic c-Kit over-expression (c-KitβTg) or c-Kit knockdown by point-mutation
(Wv) would enhance our understanding of vascular defects in the diabetic state and
provide insight in the process of restoring vasculature following islet transplantation in
T1DM. This could be accomplished by assessing and comparing c-Kit knockdown and
overexpression models’ vasculature and pancreatic function by protein and RNA analysis
from isolated islets, as well as vasculature morphology through PECAM-1 or collagen IV
staining, then examing whether crossing the two mouse models would result in recovery
of vascular impairment.
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Figure 4.1 Schematic of proposed model involving SCF-stimulated c-Kit activation
through the convergence of the PI3K/Akt and p38 MAPK pathways to increase
VEGF-A production.
SCF binding to the receptor tyrosine kinase c-Kit results in homodimerization of the
receptor and subsequent autophosphorylation on tyrosine residue 719. This allows for
recruitment of PI3K/Akt via its pleckstrin homology (PH) domain and phosphorylation of
Akt at serine residue 473, resulting in its kinase activity. Akt is able to direct
phosphorylation of mTOR on serine residue 2448, allowing it to bind to Raptor protein,
forming the bioactive mTORC1 complex, and/or phosphorylate Gsk3β at serine residue 9
to inactivate it. The mTORC1 complex is then able to act upon NfκBp65 at serine residue
534, resulting in its translocation to the nucleus and increased transcription of HIF-1α, a
transcription factor that promotes VEGF-A production and secretion. Inactivated Gsk3β
is unable to degrade β-catenin which allows β-catenin to translocate into the nucleus and
promote increased VEGF-A transcription. p38 MAPK is another molecule that is
activated when bound via its SH2 domain to activated c-Kit. p38 MAPK is then
phosphorylated at threonine residue 180 and tyrosine residue 182, allowing it to further
stimulate mTOR phosphorylation and mTORC1’s downstream effects.
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4.1 Do c-Kit and VEGF-A Co-localize in SCF-treated INS-1
Cells?
It has been reported that c-Kit is expressed in INS-1 cells (Rachdi et al., 2001), the cell
line used in this work. Previous reports showed that SCF and VEGF are co-localized in
cancer cells derived from human metastatic melanoma (Heissig et al., 2003). In order to
confirm that c-Kit and VEGF-A are located in the same cell population, we first used
double immunofluorescence staining to show the co-localization of VEGF-A and c-Kit in
INS-1 cells. Our data from live cell staining on cover slips demonstrated that both c-Kit
and VEGF-A co-localized in these cells, but distribution differed (Figure 3.1). c-Kit
expression was located primarily near cell membranes, with some staining of internalized
c-Kit receptors, while VEGF-A stained predominantly in the cytoplasm of cells. These
data built a case which prompted us to examine whether there is a relationship between
activation of the c-Kit receptor and modulation of VEGF-A production in the following
experiments.

4.2 Can VEGF-A Production and Release be Stimulated by
Exogenous SCF Activaiton of c-Kit in vitro?
Upon treatment with SCF at a variety of concentrations, a VEGF-A ELISA determined
that there was, in fact, an increase in VEGF-A release in a dose- and time dependent
fashion into cell culture medium after SCF treatment (Figure 3.2 and 3.3). A significant
increase in culture medium VEGF-A levels was observed at 24 h of SCF-stimulation
compared to controls (Figure 3.3). This delayed response was likely due to the fact that
INS-1 is a cancer cell line and contains a high basal level of VEGF-A production and
release, compared to that found in isolated islets or animal models. Despite the fact that
cancer cell lines, such as INS-1, have a high basal VEGF-A secretion rate (Bellamy et al.,
1999; Dankbar et al., 2000), previous studies have used this cell line to demonstrate
quantifiable stimulation of VEGF-A production and secretion, specifically by the
induction of HIF-1α by oxidative stress (Moritz et al., 2002; Gosh et al., 2010). A study
reported that HIF-1α expression was upregulated following SCF stimulation in a
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hemetopoietic cell line, which yielded a transcriptionally active form of HIF-1α, able to
modulate VEGF, induced through stimulation of c-Kit and subsequent activation of the
PI3K and Ras/MEK/Erk pathways (Pedersen et al., 2008). Similarly, observations made
in our study demonstrated that INS-1 cells treated with SCF exhibited significantly
increased levels of Hif-1α and Vegf-A mRNA (Figure 3.4A) and VEGF-A release
(Figure 3.2, 3.3). Intracellular VEGF-A content was shown to increase ~25%, but did not
reach statistical significance (Figure 3.4B). One possible explanation for this observation
is that increased VEGF-A production was secreted immediately in response to
physiological stimuli, as demonstrated in cultured mouse islets responding to low glucose
culture conditions (Xiao et al., 2013). Furthermore, performing this study under hypoxic
conditions would likely exacerbate VEGF-A production and secretion due to a lack of
VHL-mediated inhibition and degradation of factors such as HIF-1α that serve to
promote angiogenic processes.
The mechanism by which VEGF-A is secreted from β-cells is not well-understood but it
has been reported that, in bone marrow-derived mast cells, release of VEGF-A is largely
mediated by hypoxia-triggered signaling pathways that depend on the Src family kinases
and PI3K (Garcia-Roman et al., 2010). Furthermore, in a VEGF reporter study performed
in Hep3B cells, it was demonstrated that the 5’-flanking region of the VEGF gene is able
to functionally interact with HIF-1, composed of the HIF-1α and HIF-1β subunits, on at
least two HIF-1 binding sites (Forsythe et al., 1996), further implicating HIF-1α as a key
regulator of VEGF-A . We have previously shown, in vitro and in vivo, that c-Kit
activation by SCF could target the PI3K/Akt signaling pathway (Li et al., 2006; Feng et
al., 2011; Feng et al., 2012). It was thought that SCF-induced VEGF-A release in INS-1
cells might also be regulated by activation of c-Kit and downstream of the PI3K/Akt
signaling pathway as discussed below.
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4.3 Is the PI3K/Akt/mTOR Signaling Pathway Involved in
VEGF-A Regulation?
4.3.1

c-Kit Receptor Phosphorylation

c-Kit is able to mediate a variety of effects on various cell types in a variety of cell
lineages and cell types in murine and human models. Upon ligand-binding, the
transmembrane receptor is phosphorylated on tyrosine residue 719 in the kinase insert
region, allowing it to associate with the p85 subunit of PI3K, containing two SH2
domains, to induce its phosphorylation and activation of more downstream signaling
molecules by activity of the 110 kDa catalytic subunit (p110) (Serve et al., 1994; Yee et
al., 1994). Expectedly, 24 hours following SCF treatment, INS-1 cells had significantly
increased phosphorylation of c-Kit at tyrosine residue 719, indicating that SCF and c-Kit
interaction results in activation of the receptor tyrosine kinase (Figure 3.6A).

4.3.2

Akt Phosphorylation

Activation of PI3K results in the production of phosphatidylinositol-3,4,5-triphosphate
(PIP3), which is able to recruit signaling proteins with pleckstrin homology (PH)
domains, consisting of approximately 100 amino acids, to the membrane, such as Akt
(Vara et al., 2004). Akt is expressed as three isoforms (Akt1/2/3) that exhibit highly
overlapping functions in regulation of factors such as cellular growth, glucose
homeostasis, and neuronal development, and feature many common phosphorylation sites
due to their shared amino-terminal PH domain (Manning and Cantley, 2007; Gonzalez et
al., 2009). Recruitment of Akt by PIP3, the lipid product of activated PI3K, results in
conformational changes in Akt and exposure of two of its essential phosphorylation sites,
threonine residue 308 and serine residue 473 (Andjelkovic et al., 1995; Kandel et al.,
1999; Brazil and Hemmings, 2001). While phosphorylation of threonine residue 308,
located within the activation loop of the kinase domain, is required for activation of Akt,
phosphorylation of serine residue 473, located at the C-terminus, is thought to be required
for full kinase activity (Kandel et al., 1999; Widenmaier et al., 2009). 3phosphoinositide-dependent kinase (PDK1), a PIP3-dependent kinase, is responsible for
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phosphorylation of threonine residue 308, while phosphorylation of serine residue 473
has been shown to be dependent on the mTOR complex 2 (mTORC2), containing mTOR,
rictor, and mLST8 (Hresko et al., 2005; Sarbassov et al., 2006). PDK1 and mTORC2
activity play a role in a variety of cellular processes including cell death regulation, cell
cycle progression, and cell growth (Juan et al., 2004). Our lab has previously determined
that activation of c-Kit led to phosphorylation of Akt at serine residue 473, but not
threonine residue 308 (Feng et al., 2011). Therefore, we examined phosphorylation of
Akt on serine residue 473 after SCF stimulation, which showed a significant increase in
the activity of Akt in association with VEGF-A release (Figure 3.6B). Lys294002 was
used as a potent inhibitor of PI3K, and it was found that VEGF-A release was attenuated
to control levels at a sufficient dosage (10 μmol/L) despite SCF stimulation (Figure
3.10C). This further confirmed the involvement of the Akt signaling pathway in SCFstimulated VEGF-A release. However, whether PDK1 and mTORC2 activity is involved
in this regulatory process was not examined in this work, thus it would be important to
investigate in future research in order to verify whether SCF/c-Kit-induced VEGF-A
release requires activation of multiple downstream kinases.

4.3.3

mTOR Signaling Pathway

The mammalian target of rapamycin (mTOR) is the most-examined downstream
substrate of Akt. Akt exerts a number of mechanisms to regulate mTOR, either directly
through phosphorylation of the substrate, or by modulation of other regulatory
mechanisms. Akt is able to indirectly activate mTOR through phosphorylation of
tuberous sclerosis complex 2 (TSC2) resulting in its inhibition and inability to
heterodimerize with tuberous sclerosis complex 1 (TSC1) (Inoki et al., 2003; Tee et al.,
2003). Once TSC2 is inhibited and unable to form its active complex with TSC1, it is
unable to hydrolize GTP to GDP in Ras homolog enriched in brain (Rheb). Without this
negative regulation of Rheb, it is able to remain in its GTP-bound state, allowing for
increased activation of mTOR (Inoki et al., 2003; Manning and Cantley, 2003). It has
been proposed that for full TSC2 inactivation, Akt must play a role in regulation, through
direct inhibition of TSC2 by phosphorylation, which it can also influence by increasing
ATP levels (Hahn-Windgassen et al., 2005). In this work, mTOR activation was assayed
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by examining phosphorylation of serine residue 2448, which has been demonstrated to be
crucial in Akt-mediated mTOR activation (Nave et al., 1999; Inoki et al., 2002). As
expected, due to increased activation of Akt, mTOR phosphorylation/activation was
significantly increased following SCF treatment in INS-1 cells (Figure 3.7A). Inhibiting
the mTOR pathway with rapamycin at a sufficient dosage (20 nmol/L) could block SCFinduced VEGF-A release in INS-1 cells (Figure 3.11C). Furthermore, it has been shown
that insulin binding to its receptor increases Akt-mediated phosphorylation of TSC2 at
serine residues 939 and 981, resulting in the dissociation of the TSC1/2 complex (Cai et
al., 2006). Since INS-1 cells are able to produce greater amounts of insulin, and c-Kit
activation has been linked to increased insulin production and expression (Rachdi et al.,
2001), it is possible that mTOR activation was compounded by these factors, creating an
even stronger response than hypothesized. Thus, it would be critical, for future study, to
examine the effect of c-Kit activation on the TSC1/2 complex in this context. mTOR can
bind to Raptor to form the mTORC1 complex, controlled by GTP-bound Rheb amongst
other signaling molecules, or mTOR can bind to Rictor to form the mTORC2 complex,
which is activated by a variety of RTKs and can interact with Akt to regulate it
(Sarbassov et al., 2005). The exact function and mechanism by which mTORC2 is
activated and exerts its effects is not well-known, but in this work, mTORC1 and its
downstream effects are of particular relevance to VEGF-A regulation in INS-1 cells.

4.3.4

P70S6K and NfκB of the mTOR-targeted Signaling Pathway

mTOR is an important regulator of a variety of cellular functions, including cell growth
and proliferation. It is located downstream of the PI3K/Akt pathway, and its most
important substrate is p70S6K. Overall the pathway is implicated not only in cell
proliferation, growth, differentiation and survival (Schmelzle and Hall, 2000), but also
angiogenesis and tumor neovascularisation, making it a likely candidate for VEGF-A
modulation in our current study (Maffucci et al., 2005). Once the mTORC1 complex is
formed, mediated by Rheb due to the Akt-mediated inhibition of TSC2, it can act upon
the hydrophobic motif of p70S6K, phosphorylating it at threonine residue 389, an effect
that is confirmed to be attenuated in siRNA-mediated PI3K p110 catalytic subunit
knockdown (Matheny and Adamo, 2009). In this work, phosphorylated p70S6K was
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significantly increased following SCF treatment in INS-1 cells, further confirming the
functional activation of mTOR (Figure 3.7B). It should be noted that P70S6K can also be
regulated by phosphorylation of threonine residue 229 by PDK1, which also serves as a
regulatory protein in PI3K signaling (Pullen et al., 1998). In future work, PDK1 activity
should be analyzed to ensure changes in mTOR signaling are indeed modulated by c-Kitmediated PI3K/Akt activation.
In addition to p70S6K, mTOR is also able to target the transcription factor NfκB, first
identified as a nuclear factor that binds the κ light chain enhancer in B-cells, but thought
to have a role in a variety of cellular functions including angiogenic processes and
immune responses (Jung et al., 2003B; Shinojima et al., 2007). NfκB signal transduction
is reliant on phosphorylation and degradation of the IκB protein by the IKK complex,
consisting primarily of IKKα and IKKβ. Once the IKK complex phosphorylates the IκB
protein, it is marked for proteasomal degradation, allowing for NfκB to migrate to the
nucleus and bind to target sequences (Hayden and Gosh, 2004). It has been reported that
Akt is able to activate NfκB transcriptional activity (Madrid et al., 2001; Sizemore et al.,
2002) and direct its nuclear accumulation (Gustin et al., 2004). A study has demonstrated
that insulin is important in mediating an interaction between mTOR and IKKα, which is
essential for NfκB transcriptional modulation (Dan and Baldwin, 2008). NfκBp65 has
been shown, in normoxic conditions, to respond to activation by the PI3K/Akt/mTOR
axis and mediate HIF-1α transcription, thought to be a driving force in VEGF-A
regulation (Jung et al., 2003a; Jung et al., 2003b; Bonello et al., 2007). It has been
demonstrated that NfκBp65 is phosphorylated at serine residue 534, mediated by IκK
kinase α and β, necessary for releasing NfκB as an active transcription factor, able to
increase transcription of HIF-1α (Bonello et al., 2007; Bai et al., 2009). In this work,
NfκBp65 phosphorylation in SCF-treated INS-1 cells was found to be increased and
transcriptionally active, modulating HIF-1α expression and increasing VEGF-A
production (Figure 3.7C).
Taken together, these results suggest that following SCF stimulation of c-Kit in INS-1
cells, the PI3K/Akt/mTOR axis is able to modulate a variety of downstream signaling
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proteins as confirmed by an inhibitory study, in order to increase the production of
angiogenic transcription factor HIF-1α and promote VEGF-A production and release.

4.4 Is the Akt/Gsk3β/ β-catenin Signaling Pathway Involved in
SCF-induced VEGF-A Production and Release in INS-1
Cells?
Our lab previously showed that the Akt/Gsk3β signaling pathway plays a key role in
regulation of β-cell function and survival in both c-Kit mutation and over-expression
mouse models (Feng et al., 2011; Feng et al., 2012), thus we have investigated whether
this signaling pathway is also involved in SCF-mediated VEGF-A production in vitro.
The serine/threonine kinase, glycogen synthase kinase 3 (Gsk3) consists of two highly
homologous isoforms: Gsk3α and Gsk3β. These isoforms are similarly regulated and able
to compensate for one another in some functions, sharing nearly identical sequences in
their kinase domains (Shaw et al., 1997; Jope and Johnson, 2004; Thornton et al., 2008).
However, studies have indicated that Gsk3β is a substrate that is inactivated by active Akt
when phosphorylated at the N-terminal serine residue 9 (Shaw et al., 1997; Feng et al.,
2012). Apart from active, unphosphorylated Gsk3β’s ability to regulate glycogen
synthase, it has been implicated in a variety of cellular processes, mediating cell cycle,
motility and apoptosis. Its dysregulation has been linked to several pathologies, including
the onset of cancer and diabetes (Jope and Johnson, 2004). Studies on Gsk3β inhibition in
isolated adult human and rat islets have indicated that Gsk3β pharmacological
inactivation results in increased islet cell proliferation (Liu et al., 2009). In vivo, mice
with a β-cell-specific Gsk3β overexpression displayed reduced β-cell mass and function,
while mice with a heterozygous c-Kit point-mutation (c-KitWv/+) were treated with 1AKP, a Gsk3β inhibitor, and were able to recover β-cell function, in terms of proliferative
capacity and insulin secretion, as well as maintain normal glucose processing (Liu et al.,
2008; Feng et al., 2012). Taken together, these studies indicate that Gsk3β inactivation
plays a crucial role in β-cell function and survival, and is modulated by the PI3K/Akt
pathway through c-Kit stimulation. We examined the level of Gsk3β phosphorylated at
serine residue 9 in SCF-treated INS-1 cells and found that its phosphorylation was
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significantly increased (Figure 3.8A), along with increased total β-catenin (Figure 3.8B),
indicating that SCF/c-Kit-induced VEGF-A production is associated with Akt/Gsk3β
phosphorylation.
It has been shown that modulation of the Gsk3β/β-catenin axis in a variety of cell types
has resulted in the initiation of several angiogenic processes, including expression of
VEGF-A/C, and increased phosphorylation of the VEGF receptor 2 (VEGFR-2) (Skurk et
al., 2005; Leung et al., 2006). Furthermore, studies have demonstrated that Akt is able to
directly phosphorylate β-catenin at serine residue 552, in vitro and in vivo, causing βcatenin to dissociate from cell-cell contacts, accumulating in both cytosol and the nucleus
(Sharma et al., 2002; Fang et al., 2007). Phosphorylation of this site was not examined in
this work, and would be beneficial to evaluate in future research.

4.5 Is the MAPK/Erk Signaling Pathway Involved in SCFinduced VEGF-A Production and Release in INS-1 Cells?
In addition to stimulation of the PI3K/Akt/mTOR axis by the mechanisms discussed
previously, there are thought to be other converging pathways by which VEGF-A
regulation is synergistically controlled from c-Kit activation. It has been reported that
SCF stimulation in bone marrow stem cells and cardiac stem cells induced cell migration
due to its ability to activate MAPKs, including ERK1/2, p38 MAPK, and JNK (Kuang et
al., 2008). There are reports in human bone marrow mesenchymal stem cells and adipose
progenitor cells are able to produce VEGF, HGF, and IGF-I by a p38 MAPK-dependent
mechanism (Wang et al., 2006). Additionally, it has been established that p38 MAPK and
Akt play a synergistic role in mTOR activation, necessary for VEGF-A modulation, in a
variety of cell types, including the human osteosarcoma cell line SaOS, the human
fibroblast HCA2 cell line and mouse embryonic fibroblast cell lines (Hernandez et al.,
2011). Based on these reports, levels of p38 MAPK phosphorylation were examined, and
found to have increased following SCF treatment in INS-1 cells (Figure 3.9B). However,
the phosphor-Erk42/44 level in SCF-treated INS-1 cells showed no changes (Figure
3.9A), possibly due to inhibition by NfκB for which it may act as a compensatory
mechanism (Frede et al., 2006). Additionally, some avenues of research have identified c-
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Kit activation-dependent p42/44 MAPK signaling to peak shortly following c-Kit
activation (<1 hour), and to attenuate over time in the absence of sustained c-Kit
activation (Zheng et al., 2011). Moving forward, it would be interesting to examine its
activity in comparison to the rest of the pathway at a much shorter time-point.

4.6 Does Down-regulation of c-Kit Expression Affect VEGF-A
Production?
To further test whether down-regulation of c-Kit expression could influence VEGF-A
production and release, a c-Kit siRNA study was performed in this study. In this work
total c-Kit was found to be significantly reduced (Figure 3.12B) and activated c-Kit,
phosphorylated at tyrosine residue 719 was significantly reduced (Figure 3.12C). RTPCR analysis for RNA quality showed that there was a ~45% decrease in c-Kit RNA in
c-Kit siRNA-treated groups, compared to control siRNA-treated groups, but did not reach
statistical significance (Figure 3.12A). While this is indicative of inefficient transfection,
likely confounded by growth factors found in the transfection medium and the use of 3
merged complexes of c-Kit siRNA that may have variable efficiency, it is still possible to
see a significant effect on downstream pathways due to c-Kit activation’s profound effect
on β-cell physiology, as demonstrated previously using c-KitWv/+ mice with a
heterozygous point-mutation which knocked down ~50% of c-Kit function in these
animals, but was still able to result in impaired β-cell growth and function even at 8
weeks of age (Krishnamurthy et al., 2007). As predicted, the minor reduction of c-Kit
coincided with a small decrease in VEGF-A accumulation in culture medium (Figure
3.13C). Analysis of Hif-1α and Vegf-A transcript levels showed a trend toward decrease,
but did not reach significance (Figure 3.13A). Taken together, these results suggest that
there was transfection inefficiency, possibly due to the transient transfection technique
utilized and, possibly, requirement of a longer time-point to see an effect on VEGF-A
signaling. Similar to the SCF-treated conditions, it was found that siRNA-treated cells
had slightly decreased levels of intracellular VEGF-A, however it did not reach statistical
significance (Figure 3.13B), reflected in morphological analysis of VEGF-A and insulin
double immunofluorescence staining (Figure 3.14BC). It has indeed been demonstrated
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that, while VEGF-A is regulated by HIF-1α production, Von Hippel-Lindeau tumor
suppressor (pVHL) is able to ubiquitinate and degrade HIF-1α by its E3 ubiquitin-protein
ligase activity, an oxygen-dependent process (Manalo et al., 2005). Since c-Kit siRNAtreatment does not affect oxygen and, instead, suppresses HIF-1α production by c-Kit
inactivation, it is possible that pVHL production is dysregulated and, thus, HIF-1α
degradation is less profound under these conditions. It has also been shown that VHLhigh hemangioblastomas are found to be positive for stem cell markers such as CD34 and
CD133 (Chan et al., 2005). Since pVHL levels were not examined in this work, it would
be beneficial to determine whether a reduction in c-Kit could affect pVHL production
and be responsible for the minor change observed in regard to Hif-1α and Vegf-A
transcript levels. It should be noted, however, that upon gross examination, both insulin
and VEGF-A stain intensity seemed to be lower in the siRNA-treated group (Figure
3.14A), but this did not transfer to a significantly reduced level of VEGF-A protein.
Levels of phosphorylated Akt, phosphorylated mTOR, phosphorylated p70S6K, and
phosphorylated NfκB were all significantly reduced followed siRNA treatment (Figure
3.15). These changes were reflected further downstream with significant decreases in
Gsk3β phosphorylation, and total β-catenin levels (Figure 3.16). Previous studies have
noted decreases in many of these proteins in vivo, using the heterozygous c-Kit
knockdown model (Krishnamurthy et al., 2007; Feng et al., 2012A). This further suggests
that after extended siRNA knockdown time, it is possible that these changes would
manifest as decreases in the final product, VEGF-A, or its key mediator, HIF-1α. p38
MAPK phosphorylation was not significantly different when compared to controls
(Figure 3.16) suggesting again that the transfection time/efficiency was not sufficient to
elicit an inhibitory response from c-Kit knockdown. It has been reported that p38 MAPK
and p42/44 MAPK are involved in regulating intracellular calcium levels by PKC, which
is largely related to secretion rate of angiogenic factors (Ito et al., 1998; Takahashi et al.,
2001). Since p38 MAPK was reduced by ~54%, and p42/44 MAPK was not examined in
the siRNA study, it’s possible that insufficiently reduced activation of these signaling
molecules resulted in only minor changes to VEGF-A production and secretory capacity.
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4.7 Limitations of the Study and Methodology
While this study highlights a correlation between c-Kit activity and modulation of the
angiogenic factor VEGF-A, there are several drawbacks and limitations to this work.
First, the INS-1 cell line used in this study is a good model for pancreatic β-cells, but are
still physiologically different. This cell line is able to attain an 8-fold maximal insulin
secretion response to glucose and has only marginal increases in cAMP levels in response
to glucose (Yang et al., 2004). Furthermore, INS-1 cells have been shown to reach a
plateau of insulin secretion once they reach a high level of confluence, suggesting that if
cell density is affected by treatment, it may affect insulin secretion and cell health,
confounding experimental results (Hectors et al., 2013). INS-1 cells, by their nature, lack
endothelial cells to create a microenvironment, which results in a loss of feedback that βcells would receive following changes in hormone secretion, especially since they lack
receptors for VEGF-A, the hormone of interest (Inoue et al., 2002). In order to determine
function of VEGF-A in vessel formation, it would be possible to co-culture the INS-1 cell
line with an endothelial cell line, such as human microvascular endothelial cells
(HMECs) or human umbilical cord endothelial cells (HUVECs), with or without
exogenous SCF stimulation, and monitor their effect on endothelial cell organization,
fenestration and caveolae formation, modulation of cell adhesion molecules, VEGF-A
secretion changes, and antiangiogenic factor secretion (e.g. thrombospondin-1).
Secondly, while it was established that c-Kit and VEGF-A are both expressed in this cell
population, an immunoprecipitation was not performed and thus, a direct link cannot be
established between the two proteins, leaving room for the examination of other factors
that may be responsible for the changes in VEGF-A levels observed. In particular,
insulin-like growth factor 1 and 2 (IGF-1/2) signaling has been implicated in VEGF-A
regulation and angiogenesis, specifically by HIF-1α induction, but were not examined in
this work (Stoeltzing et al., 2003; Bjorndahl et al., 2005; Ma et al., 2006). Furthermore,
insulin signaling has been shown to play a role in the modulation of VEGF-A in a variety
of tissue types, and the insulin receptor is thought to crosstalk with c-Kit, thus, opening
another potential avenue for research (Lu et al., 1999; Hale et al., 2013). It is of particular
interest to examine the involvement of these signaling pathways to investigate possible
cross-talk with c-Kit and more insight into how angiogenic signaling is controlled in β-
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cells. Finally, the c-Kit siRNA transfection showed minimal knockdown of c-Kit, its
downstream signaling molecules and VEGF-A, thus dosage and treatment time need to
be reexamined to provide a more efficient knockdown and perhaps a more potent effect
on VEGF-A production and release.

4.8 Conclusion and Future Direction
Understanding the mechanisms that regulate VEGF-A production and release are
essential in reaching the goal of manipulating their activity to recover disrupted islet
vasculature following trauma or transplant. This study has demonstrated that c-Kit
activation, by SCF stimulation, is able to increase the proteins and targets of the
PI3K/Akt/mTOR axis in order to have transcriptional effects on a functional model of βcells in vitro. The results of this study suggest that siRNA-mediated knockdown of c-Kit
is able to attenuate this effect to some extent, but further work with, perhaps, a modified
transfection procedure would yield more conclusive results. More importantly, in order to
confirm that SCF/c-Kit interaction plays an essential role in mediating VEGF-A
production, combining siRNA-mediated c-Kit knockdown and SCF stimulation should be
considered to determine whether knockdown following stimulation would attenuate the
PI3K/Akt/mTOR-mediated VEGF-A production. Furthermore, this study was able to
demonstrate that inhibition of c-Kit’s downstream targets was indeed able to attenuate
VEGF-A production, but analysis of RNA and protein in these inhibition studies would
be necessary to confirm that the pathway used to regulate VEGF-A expression is, in fact,
PI3K/Akt/mTOR (Figure 4.1). Additionally, it should be noted that c-Kit is able to signal
other pathways and, to fully understand its effect on VEGF-A modulation, changes in
pathways such as Wnt signaling and MAPK pathways should be further examined. Wnt,
specifically, is able to stimulate β-catenin nuclear translocation, and has been shown to
play a role in blood cell formation in hematopoietic stem cell populations lacking c-Kit
(Trowbridge et al., 2010). Thus, stimulation of cultured INS-1 cells by exogenous Wnt
with and without c-Kit blockade would be an interesting avenue of research to pursue in
the future. Finally, future work should take these concepts and apply them to primary
islet cell culture studies and in vivo models in order to determine the effect of c-Kit
activation and knockdown on a living system in regard to vascular changes, changes in
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protein signaling, and possibly the effects of VEGF-mediated inflammatory responses. A
thorough study of c-Kit-mediated VEGF modulation will allow researchers to work on
developing cell-based therapies for revascularization of pancreatic islets.
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Appendices
Appendix I – Phase contrast Images Prior to and Following Inhibitor Treatment

Phase-contrast images demonstrating consistant cell confluency between controls and
cells treated with (A) Lys294002 at varying concentrations with or without SCF, or (B)
rapamycing at varying concentrations with or without SCF.
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Appendix II – The Melting Curves and Derivative Melting Curves of qRT-PCR Products

Hif-1α
(A)

VEGF-A

(B)

(A)

(B)

18S
(A)

(B)

(A) The melting curves and (B) derivative metling curves of Hif-1α, VEGF-A, and 18S
show that qRT-PCR assays have amplified the target sequences with high specificity.
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Appendix III – Classification 2 Laboratory Permit Summary
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Appendix IV – Biosafety Approval

116

Curriculum Vitae

ALEXEI Popell
EDUCATION
MASTER OF SCIENCE
Physiology and Pharmacology – Western University

2012-Present
London, ON

BACHELOR OF MEDICAL SCIENCE
Medical Science – University of Western Ontario

2007-2011
London, ON

HONOURS AND AWARDS
Western Graduate Research Scholarship

September 2012-Present

Faculty of Graduate Studies
Western University

PRESENTATIONS AND POSTERS
Popell A, Feng ZC, Li J, Wang R. “SCF/c-Kit interaction regulates VEGF-A production
via concurrent Akt/mTOR and p38 MAPK pathway in β-cells”
Accepted for presentation at:
 London Health Research Day
 Physiology and Pharmacology Research Day
 Diabetes Research Day

March 2014
November 2013
November 2013

